Gi Dynamics (GIDYL) 10-K 27 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 12, 2020	Jun. 28, 2019
Document Information Line Items
Entity Registrant Name	GI DYNAMICS, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		36,598,291
Entity Public Float			$ 19,603,047
Amendment Flag	false
Entity Central Index Key	0001245791
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	000-55195
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,499	$ 3,806
Restricted cash	30	30
Prepaid expenses and other current assets	1,230	530
Total current assets	3,759	4,366
Property and equipment, net	42	63
Right-of-use operating lease, net of amortization	386
Total assets	4,187	4,429
Current liabilities:
Accounts payable	636	1,050
Accrued expenses	1,353	1,645
Short term debt to related party, net of discount	5,000	4,960
Derivative liabilities	10	51
Short term lease liabilities	169
Total current liabilities	7,168	7,706
Long term debt to related party, net of discount		168
Long term lease liabilities	217
Total liabilities	7,385	7,874
Commitments and contingencies (Note 10)
Stockholders’ deficit:
Common stock, $0.01 par value – 75,000,000 and 50,000,000 shares authorized at December 31, 2019 and 2018, respectively; 36,598,291 and 19,277,545 shares issued and outstanding at December 31, 2019 and 2018, respectively	366	193
Additional paid-in capital	280,928	263,521
Accumulated deficit	(284,492)	(267,159)
Total stockholders’ deficit	(3,198)	(3,445)
Total liabilities and stockholders’ deficit	$ 4,187	$ 4,429

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	50,000,000
Common stock, shares issued	36,598,291	19,277,545
Common stock, shares outstanding	36,598,291	19,277,545

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating expenses:
Research and development	$ 4,225	$ 1,947
Sales and marketing	22	866
General and administrative	5,295	4,809
Total operating expenses	9,542	7,622
Loss from operations	(9,542)	(7,622)
Other income (expense):
Interest income	3	29
Interest expense	(6,178)	(1,151)
Foreign exchange gain	11	13
Income (expense) from diverted funds and insurance claim, net		224
Re-measurement of derivative liabilities	(1,683)	482
Gain on write-off of accounts payable	101
Other expense, net	(7,746)	(403)
Loss before income tax expense	(17,288)	(8,025)
Income tax expense	45	13
Net loss	$ (17,333)	$ (8,038)
Basic and diluted net loss per common share (in Dollars per share)	$ (0.67)	$ (0.59)
Weighted-average number of common shares used in basic and diluted net loss per common share (in Shares)	25,886,615	13,699,585

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017	$ 112	$ 255,294	$ (259,121)	$ (3,715)
Balance (in Shares) at Dec. 31, 2017	11,157,489
Issuance of shares upon private placement, net of issuance costs	$ 81	6,353		6,434
Issuance of shares upon private placement, net of issuance costs (in Shares)	8,120,056
Beneficial conversion feature discounts associated with 2018 Note		1,007		1,007
Relative fair value of warrant issued with 2018 Note		743		743
Stock-based compensation expense		124		124
Net loss			(8,038)	(8,038)
Balance at Dec. 31, 2018	$ 193	263,521	(267,159)	(3,445)
Balance (in Shares) at Dec. 31, 2018	19,277,545
Reclassification of derivative liabilities to additional paid-in capital upon stockholder approval		5,785		5,785
Issuance of common stock upon conversion of notes payable to related party	$ 91	5,913		6,004
Issuance of common stock upon conversion of notes payable to related party (in Shares)	9,072,197
Issuance of common stock upon exercise of related party warrants	$ 82	5,321		5,403
Issuance of common stock upon exercise of related party warrants (in Shares)	8,248,549
Stock-based compensation expense		388		388
Net loss			(17,333)	(17,333)
Balance at Dec. 31, 2019	$ 366	$ 280,928	$ (284,492)	$ (3,198)
Balance (in Shares) at Dec. 31, 2019	36,598,291

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating activities:
Net loss	$ (17,333)	$ (8,038)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	32	35
Loss on disposal of leasehold improvements		2
Stock-based compensation expense	388	124
Non-cash interest expense	6,173	683
Re-measurement of derivative liabilities	1,683	(18)
Changes in operating assets and liabilities:
Accounts receivable		40
Prepaid expenses and other current assets	(700)	(265)
Accounts payable	(414)	(141)
Accrued expenses	(441)	265
Deferred revenue		(11)
Net cash used in operating activities	(10,612)	(7,324)
Investing activities
Purchases of property and equipment	(11)	(3)
Net cash used in investing activities	(11)	(3)
Financing activities
Proceeds from issuance of common stock, net of issuance costs		6,434
Debt issuance costs	(87)	(85)
Proceeds from exercise of related party warrants	5,403
Proceeds from short term and long term debt, related party	4,000	1,750
Net cash provided by financing activities	9,316	8,099
Net increase (decrease) in cash and cash equivalents	(1,307)	772
Cash, cash equivalents and restricted cash at beginning of year	3,836	3,064
Cash, cash equivalents and restricted cash at end of year	2,529	3,836
Supplemental cash flow disclosures
Income taxes paid	45	12
Beneficial conversion feature discount associated with 2018 Note		1,007
Relative fair value of warrant issued with 2018 Note		743
Beneficial conversion feature discount associated with 2017 Note modification		40
Interest paid	394
Right-of-use asset obtained in exchange for lease liability	463
Conversion of notes payable to related party into common stock	6,004
Reclassification of warrant from derivative liabilities to additional paid-in capital	5,785
Fair value of warrants issued with Notes to Related Party	$ 4,061

Nature of Business

Nature of Business	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Nature of Business GI Dynamics ® Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90-95% of the worldwide diabetes population; only 5-10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus wherein little to no insulin is produced). Being overweight is a condition where the patient’s BMI is greater than 25 (kg/m 2 When considering treatment for type 2 diabetes, it is optimal to address obesity concurrently with diabetes. EndoBarrier ® The current treatment paradigm for type 2 diabetes is lifestyle therapy combined with pharmacological treatment, whereby treating clinicians prescribe a treatment regimen of one to four concurrent medications that could include insulin for patients with higher levels of blood sugar. Insulin carries a significant risk of increased mortality and may contribute to weight gain, which in turn may lead to higher levels of insulin resistance and increased levels of blood sugar. Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients. The current pharmacological treatment algorithms for type 2 diabetes fall short of ideal, creating a large and unfilled efficacy gap. The GI Dynamics vision is to make EndoBarrier the essential nonpharmacological and non-anatomy-altering treatment for patients with type 2 diabetes. The Company intends to achieve this vision by providing a safe and effective device, focusing on optimal patient care, supporting treating clinicians, adding to the extensive body of clinical evidence around EndoBarrier, gaining appropriate regulatory approvals, continuing to improve its products and systems, operating the Company in a lean fashion, and maximizing stockholder value. EndoBarrier ® Since incorporation, the Company has devoted substantially all of its efforts to product commercialization, research and development, business planning, recruiting management and technical staff, acquiring operating assets, and raising capital. The Company currently operates in one reportable business segment. Going Concern Evaluation As of December 31, 2019, the Company’s primary source of liquidity is its cash, cash equivalents and restricted cash balances. GI Dynamics is currently focused primarily on its clinical trials, which will support future regulatory submissions and potential commercialization activities. Until the Company is successful in gaining regulatory approvals, it is unable to sell the Company’s product in any market at this time. Without revenues, GI Dynamics is reliant on funding obtained from investment in the Company to maintain business operations until the Company can generate positive cash flows from operations. The Company cannot predict the extent of future operating losses and accumulated deficit, and it may never generate sufficient revenues to achieve or sustain profitability. GI Dynamics has incurred operating losses since inception and at December 31, 2019, had an accumulated deficit of approximately $284 million and a working capital deficit of $3.4 million. The Company expects to incur significant operating losses for the next several years. At December 31, 2019, the Company had approximately $2.5 million in cash, cash equivalents and restricted cash. The Company will need to restructure the terms of the 2017 Note before March 31, 2020 and raise additional capital before May 1, 2020 in order to continue to pursue its current business objectives as planned and to continue to fund its operations. The Company and Crystal Amber Fund Limited (“Crystal Amber”, a Related Party for ASX purposes) are currently in final discussions regarding the 2017 Note maturity extension. The Company is looking to raise additional funds through any combination of additional equity and debt financings or from other sources. However, the Company has no guarantee that the 2017 Note will not mature on March 31, 2020 and has no guaranteed source of capital that will accommodate repayment of the 2017 Note and sustain operations past March 31, 2020. If the 2017 Note terms are restructured, the Company anticipates operating cash being exhausted by May 1, 2020 and therefore requires additional financing. There can be no assurance that any such potential financing opportunities will be available on acceptable terms, if at all. If the Company is unable to raise sufficient capital on the Company’s required timelines and on acceptable terms to stockholders and the Board of Directors, it could be forced to cease operations, including activities essential to support regulatory applications to commercialize EndoBarrier. If access to capital is not achieved in the near term, it will materially harm the Company’s business, financial condition and results of operations to the extent that the Company may be required to cease operations altogether, file for bankruptcy, or undertake any combination of the foregoing. In addition, if the Company does not meet its payment obligations to third parties as they become due, the Company may be subject to litigation claims and its credit worthiness would be adversely affected. Even if the Company is successful in defending these claims, litigation could result in substantial costs and would be a distraction to management and may have other unfavorable results that could further adversely impact the Company’s financial condition. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The accompanying consolidated financial statements have been prepared assuming GI Dynamics will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The consolidated financial statements for the year ended December 31, 2019 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies and Basis of Presentation Principles of Consolidation The accompanying consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation. The functional currency of GID Europe Holding B.V., GID Europe B.V., GID Germany GmbH and GI Dynamics Australia Pty Ltd is the U.S. dollar. Consolidated balance sheet accounts of the Company’s subsidiaries are remeasured into U.S. dollars using the exchange rate in effect at the consolidated balance sheet date while expenses are remeasured using the average exchange rate in effect during the period. Gains and losses arising from remeasurement of the wholly owned subsidiaries’ financial statements are included in the determination of net loss. Segment Reporting The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes. GI Dynamics does not report geographic segments as there were no product sales in 2019 or 2018 and at December 31, 2019 and 2018, all long-lived assets comprised of property and equipment were held in the U.S. Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, inventory valuation including reserves for excess and obsolete inventory, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies, valuation of warrant and other derivative liabilities, estimates used to assess its ability to continue as a going concern and stock-based compensation. GI Dynamics bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Cash, Cash Equivalents and Restricted Cash GI Dynamics considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds and have a carrying amount that approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $0 and $1.1 million at December 31, 2019 and 2018, respectively. At December 31, 2019 and 2018, GI Dynamics had approximately $2 and $0.01 million, respectively, of cash and cash equivalents denominated in Australian dollars or Euros that is subject to foreign currency gain and loss. GI Dynamics has $30 thousand in restricted cash used to secure a corporate credit card account. Property and Equipment Property and equipment, are recorded at cost and are depreciated when placed in service using the straight-line method based on their estimated useful lives as follows: Asset Description Estimated (In Years) Laboratory and manufacturing equipment 5 Computer equipment and software 3 Office furniture and equipment 5 Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. GI Dynamics also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining lease term. Costs for capital assets not yet placed into service have been capitalized as construction in progress and will be depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred. Derivative Liabilities GI Dynamics examines all financial instruments to determine if the financial instrument or any component feature is a derivative under ASC 815, Derivatives and Hedging Research and Development Costs Research and development costs are expensed when incurred. Research and development costs include costs of all basic research activities as well as other research, engineering, and technical effort required to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include preapproval regulatory and clinical trial expenses. Patent Costs GI Dynamics expenses as incurred all costs, including legal expenses, associated with obtaining patents until the patented technology becomes feasible. All costs incurred after the patented technology is feasible will be capitalized as an intangible asset. As of December 31, 2019, no such costs had been capitalized since inception of the Company. GI Dynamics has expensed approximately $200 thousand of patent costs within general and administrative expenses in the consolidated statements of operations for each of the years ended December 31, 2019 and 2018. Stock-Based Compensation GI Dynamics accounts for stock-based compensation in accordance with the Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification (“ASC”) 718, Stock Compensation For awards that vest based on service conditions, GI Dynamics uses the straight-line method to allocate compensation expense to reporting periods. The grant date fair value of options granted is calculated using the Black-Scholes option pricing model, which requires the use of subjective assumptions including volatility, expected term and the fair value of the underlying common stock, among others. The assumptions used in determining the fair value of stock-based awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change, and management uses different assumptions, the Company’s stock-based compensation could be materially different in the future. The risk-free interest rate used for each grant is based on a zero-coupon U.S. Treasury instrument with a remaining term similar to the expected term of the stock-based award. Because GI Dynamics does not have a sufficient stable history to estimate the expected term, it uses the simplified method for estimating the expected term. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. Because there was no public market for GI Dynamics common stock prior to its IPO, GI Dynamics lacked company-specific historical and implied volatility information. The Company does have approximately 6 years of historical price volatility since its IPO in September 2011. Therefore, management estimates the expected stock volatility based on the to-date historical price volatility. GI Dynamics has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. GI Dynamics recognizes the impact of share-based award forfeitures only as they occur rather than by applying an estimated forfeiture rate. GI Dynamics periodically issues performance-based awards. For these awards, vesting will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company records as compensation expense, the value of the respective stock award over the implicit remaining service period. Stock awards to non-employees were accounted for in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). The measurement date for non-employee awards was generally the date performance of services required from the non-employee was complete. For non-employee awards that vest based on service conditions, the Company expensed the value of the awards over the related service period, provided the service condition was expected to be met. The Company recorded the expense of services rendered by non- employees based on the estimated fair value of the stock option using the Black-Scholes option pricing model over the contractual term of the non-employee award. At each reporting period, the fair value of unvested non-employee awards was remeasured and expensed on a straight-line basis over the vesting term of the underlying award. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718: Improvements to nonemployee share-based payment accounting) Impairment of Long-Lived Assets GI Dynamics regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist that merit adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. No such impairments were recorded in 2019 or 2018. Loss Contingencies In accordance with ASC 450, Contingencies Fraudulent Diversion of Funds and Related Insurance Proceeds In July 2018, after a third-party investigation isolated the activity, an insurance claim was filed for $271 thousand for fraudulent diversion of cash from the Company’s account into a personal account that occurred during the years 2016 through 2018. Income in the year ended December 31, 2018 represents net insurance proceeds on the claim less $22 thousand of research and development expense. GI Dynamics has since implemented internal controls to correct the identified control deficiencies associated with the fraud and the employee responsible for the diverted funds is no longer with the Company. Income Taxes GI Dynamics uses the asset and liability method of accounting for income taxes. The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between its financial reporting and the tax bases of assets and liabilities measured using the enacted tax rates in effect in the years in which the differences are expected to reverse. The Company regularly assesses the need for a valuation allowance against its deferred tax assets. Future realization of the Company’s deferred tax assets ultimately depends on the existence of sufficient taxable income within the available carryback or carryforward periods. Sources of taxable income include taxable income in prior carryback years, future reversals of existing taxable temporary differences, tax planning strategies, and future taxable income. The Company records a valuation allowance to reduce its deferred tax assets to an amount it believes is more-likely-than-not to be realized. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. The Company assesses its income tax positions and records tax benefits based upon management’s evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions where it is more-likely-than-not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more-likely-than-not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Company classifies interest and penalties on uncertain tax positions as income tax expense. Guarantees GI Dynamics has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees As permitted under Delaware law, GI Dynamics indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company maintains directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. GI Dynamics is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate it to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of December 31, 2019, and 2018, GI Dynamics had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible. As a result, no related reserves have been established. Recently Adopted Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update, or ASU No. 2016-02, Leases In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718: Improvements to nonemployee share-based payment accounting) Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement

Net Loss per Common Share

Net Loss per Common Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	3. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Potential common stock equivalents are determined using the treasury stock method. For diluted net loss per share purposes, stock options and other stock-based awards are excluded, including shares issued as a result of option exercises but which are subject to repurchase by the Company, whose effect would be anti-dilutive from the calculation. For diluted net loss per share purposes, warrants conferring the right to purchase common shares and because CDIs and common shares are interchangeable at the election of the stockholder, warrants conferring the right to purchase CDIs are excluded from diluted net loss per share calculations as inclusion would have an anti-dilutive effect. During each of the years ended December 31, 2019 and 2018, common stock equivalents were excluded from the calculation of diluted net loss per common share, as their effect was anti-dilutive due to the net loss incurred. Therefore, basic and diluted net loss per share was the same in all periods presented. The following potentially dilutive securities have been excluded from the computation of diluted weighted- average shares outstanding as of December 31, 2019 and 2018, as they would be anti-dilutive: Years Ended December 31, 2019 2018 Warrants to purchase common stock 28,532 1,972,976 Options to purchase common stock and other stock-based awards 3,331,154 1,545,719 Total 3,359,686 3,518,695

Warrants to Purchase Common Sto

Warrants to Purchase Common Stock or CDIs	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	4. Warrants to Purchase Common Stock or CDIs The following series of warrants were outstanding and exercisable at December 31, 2019 and 2018 (warrants to purchase CDIs presented as shares at a 50 CDI per share ratio): Number of underlying Exercise price December 31, Warrant Series Issue Date shares per share 2019 2018 Consultant warrant May 4, 2016 28,532 $ 0.64 28,532 28,532 2018 Warrant (1) May 24, 2018 1,944,444 $ 0.72 - 1,944,444 Total Outstanding and Exercisable 28,532 1,972,976 Weighted average exercise price $ 0.64 $ 0.72 (1) Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018 The following table rolls forward the warrant activity during the year ended December 31, 2019: Shares underlying warrants Weighted average exercise price per share Outstanding and Exercisable at December 31, 2018 1,972,976 $ 0.72 Issuance of March 2019 Warrant 1,579,696 $ 0.64 Issuance of May 2019 Warrant 4,724,409 $ 0.64 Exercise of 2018 Warrant (1,944,444 ) $ 0.72 Exercise of March 2019 Warrant (1,579,696 ) $ 0.64 Exercise of May 2019 Warrant (4,724,409 ) $ 0.64 Outstanding and Exercisable at December 31, 2019 28,532 $ 0.64 On August 21, 2019, GI Dynamics and Crystal Amber entered into a securities purchase agreement (“SPA”) for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant as detailed above and the sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI. On December 16, 2019, stockholder approval for the warrant to be issued was obtained and it was issued on January 13, 2020.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	5. Fair Value Measurements The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2019 and 2018 and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, requiring the Company to develop its own assumptions for the asset or liability. The following tables present the assets and liabilities the Company has measured at fair value on a recurring basis (in thousands): Fair Value Measurements at Reporting Date Using Quoted Prices Significant in Active Other Significant December 31, Identical Assets Inputs Inputs Description 2019 (Level 1) (Level 2) (Level 3) Liabilities Warrant liability $ 10 $ — $ — $ 10 Total liabilities $ 10 $ — $ — $ 10 Fair Value Measurements at Reporting Date Using Quoted Prices Significant in Active Other Significant December 31, Identical Assets Inputs Inputs Description 2018 (Level 1) (Level 2) (Level 3) Assets Money market funds (included in cash and cash equivalents) $ 1,097 $ 1,097 $ — $ — Total assets $ 1,097 $ 1,097 $ — $ — Liabilities Warrant liability $ 51 $ — $ — $ 51 Total liabilities $ 51 $ — $ — $ 51 The assumptions used in the Black-Scholes option pricing model to determine the fair value of the Derivative Warrant Liabilities at December 31, 2019 and 2018 were as follows: December 31, 2019 2018 Expected volatility 130.0 % 134.0 % Expected term (in years) 1.35 2.35 Risk-free interest rate 1.59 % 2.48 % Expected dividend yield — % — % The assumptions used in the Black-Scholes option pricing model to determine the fair value of the Derivative Warrant Liabilities related to the 2019 derivative warrants at each measurement period: March 2019 Warrants May 2019 Warrants March 15, March 31, June 28, May 8, June 28, 2019 2019 2019 2019 2019 Expected volatility 130.7 % 131.2 % 134.0 % 134.0 % 137.3 % Expected term (in years) 5.00 4.97 2.35 5.00 4.87 Risk-free interest rate 2.44 % 2.34 % 1.74 % 2.28 % 1.74 % Expected dividend yield — % — % — % — % — % The following table rolls forward the fair value of the derivative liabilities, where fair value is determined by Level 3 inputs (in thousands): Balance at December 31, 2017 $ 493 Decrease in fair value of 2017 Note-related conversion feature upon re-measurement (464 ) Decrease in fair value of warrants upon re-measurement (18 ) Fair value of beneficial conversion feature discount associated with 2017 Note modification 40 Balance at December 31, 2018 $ 51 Increase in fair value of warrants upon re-measurement 1,683 Fair value of warrants issued with notes to related party 4,061 Reclassification of warrants to additional paid-in capital (5,785 ) Balance at December 31, 2019 $ 10 Cash, cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, accrued expenses, short-term debt to related party and other current liabilities at December 31, 2019 and 2018 are carried at amounts that approximate fair value due to their short-term maturities and highly liquid nature of these instruments.

Concentrations of Credit Risk,

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account	12 Months Ended
	Dec. 31, 2019
Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Abstract]
Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Text Block]	6. Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account Financial instruments that subject GI Dynamics to credit risk primarily consist of cash and cash equivalents, restricted cash and accounts receivable. Cash and cash equivalent balances are all maintained with high quality financial institutions, and consequently, the Company believes that such funds are subject to minimal credit risk. The Company’s short-term investments potentially subject the Company to concentrations of credit risk. GI Dynamics has adopted an investment policy that limits the amounts it may invest in any one type of investment and requires all held investments to hold at least an A rating from a recognized credit rating agency, thereby reducing credit risk concentration. GI Dynamics reversed a $40 thousand allowance for doubtful accounts balance in 2018, resulting in no accounts receivable and allowance of doubtful accounts balances at December 31, 2019 or 2018. As such, there is no credit risk from receivables.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. Property and Equipment Property and equipment consisted of the following (in thousands): December 31, 2019 2018 Laboratory and manufacturing equipment $ 591 $ 591 Computer equipment and software 1,193 1,182 Office furniture and equipment 183 183 1,967 1,956 Less accumulated depreciation and amortization (1,925 ) (1,893 ) Total $ 42 $ 63 The Company recorded a loss on disposal of $2 thousand in connection with the expiration of its office lease and the related leasehold improvements on April 13, 2018. At December 31, 2019 and 2018, the Company had no property and equipment assets financed in any capital lease arrangement. Depreciation and amortization expense of property and equipment totaled approximately $32 thousand and $35 thousand for the years ended December 31, 2019 and 2018.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued Expenses Accrued expenses consisted of the following (in thousands): December 31, 2019 2018 Payroll and related liabilities $ 531 $ 386 Professional fees 335 573 Credit refunds 164 186 Interest payable 250 495 Other 73 5 Total $ 1,353 $ 1,645 In 2017, following the notification by MHRA, the Company notified its customers to return their inventory on hand. The Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $202 thousand of product return related costs in addition to $77 thousand of credit memos granted to customers. No related activity in 2018 and 2019 resulted in the amounts being unchanged and the Company still anticipates claims against these accruals in the future. In 2017, the Company recorded $136 thousand of interest payable on the 2017 Note. In 2018, the Company recorded $359 thousand of interest payable on the 2017 and 2018 Notes. In December 2018, the maturity of the 2017 Note was extended to March 31, 2019 in exchange for payment of $394 thousand which was the total accrued interest on the 2017 Note at December 31, 2018.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	9. Notes Payable 2017 Convertible Note Financing On June 15, 2017, the Company entered into a Note Purchase Agreement (“2017 NPA”) by and between the Company and Crystal Amber, a Related Party. Pursuant to the 2017 NPA, the Company issued and sold to Crystal Amber, a Senior Secured Convertible Promissory Note in an aggregate original principal amount of $5.0 million (the “2017 Note”). The 2017 Note accrues interest at an annually compounded rate of 5% per annum, other than during the continuance of an event of default, when the 2017 Note accrues interest at a rate of 8% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon was initially due on the original maturity date of December 31, 2018, but the maturity date was extended multiple times as described below. The 2017 Note is secured by a first priority security interest in substantially all tangible and intangible assets of the Company, including intellectual property (the “Collateral”). In the event of an uncured default, Crystal Amber, is authorized to sell, transfer, assign or otherwise deal in or with the Collateral or the proceeds thereof or any related goods securing the Collateral, as fully and effectually as if Crystal Amber were the absolute owner thereof. The ASX provided the Company with a waiver to allow all asset liens (the “Security”) to be granted to Crystal Amber, without the customary requirement of having to obtain stockholder approval for the grant of a security to a Related Party of the Company. As a result of the waiver, the Security contains a provision that provides that if an event of default occurs and Crystal Amber exercises its rights under the Security, neither Crystal Amber nor any of its associates can acquire any legal or beneficial interest in an asset of the Company or its subsidiaries in full or partial satisfaction of the Company’s obligations under the Security, or otherwise deal with the assets of the Company or its subsidiaries, without the Company first having complied with any applicable ASX Listing Rules, including ASX Listing Rule 10.1, other than as required by law or through a receiver, manager, or analogous person appointed by Crystal Amber exercising its power of sale under the Security and selling the assets to an unrelated third party on arm’s length commercial terms and conditions and distributing the cash proceeds to Crystal Amber or any of its associates in accordance with their legal entitlements. The 2017 Note was issued without stockholder approval of certain specific conversion features and as a consequence, Crystal Amber had no right to exercise any note conversion rights until stockholders approved the 2017 Note conversion terms on May 24, 2018. Subsequently, the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CDIs (i) prior to the maturity date, at the option of Crystal Amber at a conversion price calculated based on the five-day volume weighted average price of the Company’s CDIs traded on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing. In the event that the Company issues additional CDIs in a subsequent equity financing at a price per CDI that is less than the then-effective Optional Conversion Price, Crystal Amber has a 30-day option to convert at an adjusted conversion price reflecting, on a weighted average basis, the lower price per CDI. The number of CDIs that Crystal Amber may acquire upon conversion of the 2017 Note at this adjusted conversion price is limited to the number that maintains Crystal Amber’s fully-diluted ownership percentage of the Company at the same level as existed immediately preceding the applicable subsequent equity financing. In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated under the 2017 Note to pay all accrued and unpaid interest then due plus 110% of the remaining outstanding unconverted principal balance. If the change of control results in non-cash consideration, Crystal Amber may convert the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest then due into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the 2017 Note without the consent of Crystal Amber. The Company considers the change in control premium as a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premium, the fair value was considered immaterial upon issuance and at all subsequent reporting period ends. The 2017 NPA contains customary events of default including a failure to perform obligations under the 2017 NPA, bankruptcy, a decision by the board of directors of the Company to wind up the Company, or if the Company otherwise ceases to carry on its ongoing business operations. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the 2017 Note may be accelerated. The 2017 NPA and related 2017 Note documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type. The Company recorded the $5 million 2017 Note, net of debt issuance costs of $115 thousand and amortized the debt issuance costs over the life of the 2017 Note. In December 2018, the maturity date of the 2017 Note was extended to March 31, 2019 in exchange for payment of $394 thousand, which was the total interest accrued on the 2017 Note at December 31, 2018. Payment of this amount was made in January 2019. In March 2019, the maturity date of the 2017 Note was extended to May 1, 2019. In April 2019, the maturity date of the 2017 Note was further extended to July 1, 2019. In June 2019, the maturity date of the 2017 Note was further extended to October 1, 2019. On August 21, 2019, the maturity date of the 2017 Note was further extended to March 31, 2020. These extensions of maturity were evaluated under ASC 470 to determine whether debt extinguishment or debt modification accounting applies. The Company concluded that the maturity extensions did not meet the characteristics of debt extinguishments under ASC 470 and no accounting recognition was required. For the years ended December 31, 2019 and 2018, the Company recognized interest expense of $248 and $257 thousand and amortization of debt issuance costs of $43 and $0 thousand, respectively, related to the 2017 Note. 2018 Convertible Note and Warrant Financing On May 30, 2018, the Company entered into a Note Purchase Agreement (“2018 NPA”) by and between the Company and Crystal Amber. Pursuant to the 2018 NPA, the Company issued and sold to Crystal Amber a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of approximately $1.8 million (the “2018 Note”) with a maturity date of May 30, 2023. Interest accrued at an annually compounded rate of 10% per annum. On May 30, 2018, having secured stockholder pre-approval of the conversion features on May 24, 2018 per ASX Listing Rule 10.11, the entire outstanding principal balance under the 2018 Note and all unpaid accrued interest thereon was immediately convertible into CDIs, at the option of Crystal Amber at an initial conversion price of $0.018 per CDI. Subsequently, the Company issued additional CDIs in an equity financing in September 2018 at a price per CDI of $0.0144, resulting in an adjustment of the conversion price to $0.0144 per CDI. Notice to convert the 2018 Note was provided by Crystal Amber, a Related Party on June 30, 2019. The 2018 Note converted to 134,852,549 CDIs (representing 2,697,050 shares of common stock). The principal of approximately $1.8 million converted to 121,527,778 CDIs (representing 2,430,555 shares of common stock) and the accrued interest of $192 thousand converted to 13,324,772 CDIs (representing 266,495 shares of common stock). As of June 30, 2019, the conversion of the CDIs had been executed, but not yet settled with the CDIs issued and available. The CDIs were issued on July 3, 2019 and have a one-year restriction on trading on the ASX. On May 30, 2018, having secured stockholder pre-approval of the conversion features on May 24, 2018 per ASX Listing Rule 10.11, GI Dynamics issued to Crystal Amber a warrant (the “2018 Warrant”) to purchase 97,222,200 CDIs (representing 1,944,444 shares of common stock) at an initial exercise price of $0.018 per CDI. As per the 2018 Note conversion price, the warrant exercise price was subsequently adjusted to $0.0144 per CDI. The 2018 Warrant was exercised in full on August 25, 2019 for $1.4 million. The Company has evaluated the guidance ASC 480-10 Distinguishing Liabilities from Equity, A Contracts in an Entity’s Own Equity Debt with Conversion and Other Options The Company recorded the 2018 Note at issuance, net of the total debt discount of $1.8 million and amortized the debt discount over the life of the 2018 Note. For the years ended December 31, 2019 and 2018, the Company recorded accrued interest expense of $91 and $102 thousand, debt discount amortization to interest expense of $146 and $168 thousand and interest expense derived from issuance costs of nil and $85 thousand, respectively. March 2019 Convertible Note and Warrant Financing On March 15, 2019, the Company entered into a Note Purchase Agreement (“March 2019 NPA”) by and between the Company and Crystal Amber. Pursuant to the March 2019 NPA, the Company issued and sold to Crystal Amber a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of $1 million (the “March 2019 Note”) with a maturity date of March 15, 2024. Interest accrued at an annually compounded rate of 10% per annum and issuance costs related to the March 2019 NPA were $50 thousand. After the Company obtained stockholder approval to enable Crystal Amber’s conversion right under the March 2019 Note on June 30, 2019, the entire outstanding principal balance under the March 2019 Note and all unpaid accrued interest thereon was convertible into CDIs, at the option of Crystal Amber at a conversion price of $0.0127 per CDI. On June 30, 2019, Crystal Amber elected to convert the March 2019 Note into 81,070,003 CDIs (representing 1,621,400 shares of common stock) with the principal of $1 million converting to 78,740,157 CDIs (representing 1,574,803 shares of common stock) and the accrued interest of approximately $30 thousand converting to 2,329,846 CDIs (representing 46,597 shares of common stock). As of June 30, 2019, notice of the conversion had been provided by Crystal Amber and the CDIs were issued on July 3, 2019 and have a one-year restriction on trading on the ASX. Per the March 2019 NPA, the Company agreed to issue a warrant (the “March 2019 Warrant”) to Crystal Amber, pending stockholder approval, to purchase 78,984,823 CDIs (representing 1,579,696 shares of common stock) at an initial exercise price of $0.0127 per CDI. The issue of the March 2019 Warrant required the approval of stockholders and was not exercisable until its issue was approved on June 30, 2019. On August 25, 2019, a portion of the March 2019 Warrant totaling 47,244,119 CDIs (equivalent to approximately 944,882 shares of common stock) was exercised for $600 thousand. The remaining portion of the March 2019 Warrant, totaling 31,740,704 CDIs (equivalent to 634,814 shares of common stock) was exercised for approximately $400 thousand on September 30, 2019. The Company evaluated the guidance ASC 480-10, Distinguishing Liabilities from Equity, Contracts in an Entity’s Own Equity Debt with Conversion and Other Options In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated under the March 2019 Note to pay all accrued and unpaid interest then due plus 110% of the remaining outstanding unconverted principal balance. If the change of control results in non-cash consideration, Crystal Amber may convert the entire outstanding principal balance under the March 2019 Note and all unpaid accrued interest then due into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the March 2019 Note without the consent of Crystal Amber. The Company considers the change in control premium as a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premium, the fair value was considered immaterial upon issuance and at all subsequent reporting period ends. Upon approval of the conversion features of the March 2019 Note and issuance of the March 2019 Warrants on June 30, 2019, the Company remeasured the warrant liability and recorded a $576 thousand remeasurement loss to the consolidated statement of operations and then reclassified $1.4 million of fair value of March 2019 Warrant from derivative liability to equity as the warrant became immediately exercisable. The total debt discount on the March 2019 Note upon stockholder approval of its conversion feature was $1 million. The effective interest rate on the Note after the discounts was 29.4%. Upon conversion of the 2019 March Note on June 30, 2019, the Company recorded the contingent beneficial conversion feature of $129 thousand as non-cash interest expense and additional paid-in capital. For the year ended December 31, 2019, the Company accrued interest expense of $30 thousand and recorded debt discount amortization to interest expense of $1 million. May 2019 Convertible Note and Warrant Financing On May 8, 2019, the Company entered into a Note Purchase Agreement (“May 2019 NPA”) by and between the Company and Crystal Amber. Pursuant to the May 2019 NPA, the Company issued and sold to Crystal Amber a Senior Unsecured Convertible Promissory Note in an aggregate original principal amount of $3.0 million (the “May 2019 Note”) with a maturity date of May 8, 2024. Interest accrued at an annually compounded rate of 10% per annum and issuance costs related to the May 2019 NPA were $34 thousand. After the Company obtained stockholder approval to enable Crystal Amber’s, a Related Party, conversion rights under the May 2019 Note on June 30, 2019, the entire outstanding principal balance under the May 2019 Note and all unpaid accrued interest thereon was convertible into CDIs, at the option of Crystal Amber at a conversion price of $0.0127 per CDI. On June 30, 2019, Crystal Amber elected to convert the May 2019 Note into 237,687,411 CDIs (representing 4,753,748 shares of common stock). The principal of $3.0 million converted to 236,220,472 CDIs (representing 4,724,409 shares of common stock) and the accrued interest of approximately $19 thousand converted to 1,466,939 CDIs (representing 29,339 shares of common stock). As of June 30, 2019, notice of the conversion had been provided by Crystal Amber and the CDIs were issued on July 3, 2019 and have a one-year restriction on trading on the ASX. Per the May 2019 NPA, the Company agreed to issue a warrant (the “May 2019 Warrant”) to Crystal Amber, pending stockholder approval, to purchase 236,220,472 CDIs (representing 4,724,409 shares of common stock) at an initial exercise price of $0.0127 per CDI. The issue of the May 2019 Warrant required the approval of stockholders and was not exercisable until its issue was approved on June 30, 2019. A portion of the May 2019 Warrant totaling 125,739,610 CDIs (equivalent to 2,514,792 shares of common stock) was exercised by Crystal Amber for approximately $1.6 million on September 30, 2019. Another portion of the May 2019 Warrant totaling 78,740,157 CDIs (equivalent to 1,574,803 shares of common stock) was exercised by Crystal Amber for approximately $1 million on October 31, 2019. The Company evaluated the guidance ASC 480-10, Distinguishing Liabilities from Equity, Contracts in an Entity’s Own Equity Debt with Conversion and Other Options In addition, upon a change of control of the Company (other than a change of control resulting from a Qualified Financing) in which the Company’s stockholders receive cash consideration, the Company is obligated under the May 2019 Note to pay all accrued and unpaid interest then due plus 110% of the remaining outstanding unconverted principal balance. If the change of control results in non-cash consideration, Crystal Amber may convert the entire outstanding principal balance under the May 2019 Note and all unpaid accrued interest then due into CDIs at the abovementioned Optional Conversion Price. Other than as described above, the Company may not prepay the May 2019 Note without the consent of Crystal Amber. The Company considers the change in control premium as a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premium, the fair value was considered immaterial upon issuance and at all subsequent reporting period ends. Upon approval of the conversion features of the May 2019 Note and issuance of the May 2019 Warrant on June 30, 2019, the Company revalued the warrant liability and recorded a $1.1 million remeasurement loss to the consolidated statements of operations and then reclassified approximately $4.3 million of fair value of May 2019 Warrant from derivative liabilities to equity as the May 2019 Warrant became immediately exercisable. The total debt discount on the May 2019 Note upon stockholder approval was $3 million. The effective interest rate on the May 2019 Note after the discounts is 29.4%. For the year ended December 31, 2019, the Company accrued interest expense of $19 thousand and recorded debt discount amortization to interest expense of $3 million. August 2019 Share Purchase Agreement (“SPA”) On August 21, 2019, the Company entered into the August 2019 SPA by and between the Company and Crystal Amber. The August 2019 SPA detailed a timeline wherein Crystal Amber would exercise the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant. Additionally, pursuant to the August 2019 SPA, the Company issued and sold to Crystal Amber a senior unsecured convertible promissory note in an aggregate principal amount of approximately $4.6 million, or such lesser amount as may be set forth in a notice delivered by the Company to Crystal Amber (the “August 2019 Note”), to be funded on December 6, 2019, or such earlier or later date as may be requested by the Company (the “Funding Date”). In conjunction with the August 2019 Note, the Company agreed to issue to Crystal Amber a Warrant (the “August 2019 Warrant”) to purchase CDIs, subject to the receipt of required stockholder approval approving the issuance of the August 2019 Warrant and the funding of the August 2019 Note (For a detailed description of the exercises and the terms of the exiting warrants and for a description of the August 2019 Warrant, see Note 4 Warrants to purchase common stock or CDIs The August 2019 Note accrues interest at a rate equal to 10% per annum from the 2019 Note Funding Date, compounded annually, other than during the continuance of an event of default, when the August 2019 Note accrues interest at a rate of 16% per annum. The entire outstanding principal balance and all unpaid accrued interest thereon is due on the fifth anniversary of the Funding Date. Subject to the receipt of stockholder approval as required by Rule 10.11 of the ASX Listing Rules, the entire outstanding principal balance under the August 2019 Note and all unpaid accrued interest thereon is convertible into CDIs at the option of Crystal Amber at a conversion price equal to US$0.02 per CDI. In the event that the Company issues additional CDIs to a stockholder other than Crystal Amber in a subsequent equity financing at a price per CDI that is less than the conversion price under the August 2019 Note, the conversion price shall be reduced to the lowest such price per CDI. In addition, upon a change of control of the Company resulting in cash proceeds, Crystal Amber may, at its option, demand that the Company prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance. The Company may not prepay the August 2019 Note without the consent of Crystal Amber, a Related Party. If the stockholder approvals required to issue the August 2019 Warrant or to approve the conversion rights under the August 2019 Note are not obtained, the Company is obligated to prepay all accrued and unpaid interest plus 110% of the remaining outstanding unconverted principal balance on the earlier of the Funding Date or the date that is six months following the date of the stockholder meeting at which the requisite approvals were not obtained. The Company considers the change in control premium and the stockholder approval premium to each represent a cash settleable feature, thereby requiring derivative liability classification. On applying a probability adjusted present value of the premiums, the fair value was considered immaterial upon issuance at all subsequent reporting period ends. The August 2019 SPA contains customary events of default. If a default occurs and is not cured within the applicable cure period or is not waived, any outstanding obligations under the August 2019 Note may be accelerated. The August 2019 SPA and related August 2019 Note and August 2019 Warrant documents also contain additional representations and warranties, covenants and conditions, in each case customary for transactions of this type. Prior to December 6, 2019, GI Dynamics notified Crystal Amber that it had elected to receive the full amount of approximately $4.6 million under the August 2019 Note, but agreed to timing extensions. On December 16, 2019, stockholder approval was obtained pursuant to ASX Listing Rule 10.11, for the August 2019 Note conversion feature and the issuance of the August 2019 Warrant, contingent on receipt of the August 2019 Note proceeds. On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note conversion feature was immediately available to Crystal Amber. On January 13, 2020, GI Dynamics issued to Crystal Amber the August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies Lease Commitments In June 2016, the Company entered into a non-cancelable agreement to lease approximately 4,200 square feet of office space in Boston, Massachusetts. The lease commenced in June 2016 and expired in April 2018. Rent during the term was approximately $12 thousand per month. In December 2018, the Company entered into a 6-month membership agreement with WeWork for 985 square feet of office space located in Boston, Massachusetts. The committed lease term expired in May 2019 and contained a two-month cancellation provision. The WeWork agreement contained no explicit or guaranteed extension provisions. At December 31, 2018, there remained approximately $91 thousand of lease obligation, assuming the company did not cancel early. On April 22, 2019, the Company entered into a right-of-use lease for 3,520 square feet of office space in Boston, Massachusetts. The lease period contractually commenced June 1, 2019 and expires on May 31, 2022, but the space was available for occupancy on May 1, resulting in an effective period of May 2019 through May 2022, with no rent payment assessed in May 2019. The lease has defined escalating rent payments and contains no extension or expansion rights. On lease execution, the Company recorded the approximately $463 thousand present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset. The right-of-use asset will be amortized to lease expense and the liability will be reduced by the rent payments over the term of the lease. The Company’s leases generally do not provide an implicit interest rate and therefore the Company uses 10% as an estimate of its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company had no leases currently classified as finance leases or previously classified as capital leases in either reporting period. The Company’s operating lease is reflected in the balance sheets. The $102 thousand of lease expense included $7 thousand of common area rent. An additional $3 thousand of tax expense was accrued for property taxes associated with the leased facility. Other information related to leases was as follows: December 31, 2019 (in thousands) Operating cash flows from operating leases in lease liability measurement $ 148 Operating cash flows from short term leases 103 Remaining long-term lease term in years 2.4 Discount rate 10 % The maturity of the Company’s operating lease liability as of December 31, 2019 is as follows: December 31, 2019 (in thousands) 2020 178 2021 182 2022 76 Total future minimum lease payments 436 Less: imputed interest (50 ) Total liabilities $ 386 Rent expense on non-cancelable operating leases was approximately $200 and $100 thousand for the years ended December 31, 2019 and 2018, respectively.

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	11. Stockholders’ Deficit On December 19, 2019, GI Dynamics stockholders approved an increase of its authorized shares of common stock from 50 million to 75 million. As of December 31, 2019, the authorized capital stock of the Company consists of 75.5 million shares, of which 75 million shares are designated as common stock and 500 thousand shares are designated as preferred stock. In 2018, the Company received commitments for two private placements to sophisticated and professional investors in Australia, the United States and the United Kingdom, consisting of U.S. and non-U.S. persons (as defined in Regulation S (“Regulation S”) of the Securities Act of 1933 (the “Securities Act”) to raise up to approximately $6.6 million (the “2018 Placements”). The first placement (“First Quarter 2018 Placement”) consisted of a total of 58,780,619 fully paid CDIs of the Company (representing 1,175,612 shares of common stock) at an issue price of A$0.035 per CDI. The issue of CDIs under the First Quarter 2018 Placement occurred in two tranches. The first tranche closed on January 22, 2018 (US EST), pursuant to which the Company issued 28,467,063 CDIs (representing 569,341 shares of common stock) resulting in gross proceeds of approximately $781 thousand and related issuance costs of $63 thousand. The closing of the second tranche of the First Quarter 2018 Placement resulted in the raising of $824 thousand and related issuance costs of $40 thousand by the issue of 30,313,556 CDIs (representing 606,271 shares) following stockholder approval granted on February 27, 2018. There were two participants in the First Quarter 2018 Placement second tranche; Crystal Amber Fund, a related party for ASX purposes, purchased 27,391,756 CDIs. A Board member of the Company purchased 2,921,800 CDIs. The second placement (“Autumn 2018 Placement”) consisted of a total of 347,222,250 fully paid CDIs of the Company (representing 6,944,445 shares of common stock) at an issue price of A$0.020 per CDI. The investors in the Autumn 2018 Placement included certain existing investors. The issue of these CDIs occurred in two tranches. The first tranche closed on September 20, 2018 (US EST), pursuant to which the Company issued 150,000,000 CDIs (representing 3,000,000 shares of common stock) resulting in gross proceeds of approximately $2.2 million and related issuance costs of $56 thousand. The closing of the second tranche resulted in the raising of $2.8 million and related issuance costs of $12 thousand by the issue of 197,222,250 CDIs (representing 3,944,445 shares of common stock) following stockholder approval at the adjourned Special Meeting of stockholders on October 29, 2018. There were three participants in the second tranche; Crystal Amber Fund, a related party for ASX purposes, purchased 168,194,450 CDIs. Existing investors in the United States and Australia also purchased 23,819,450 and 5,208,350 CDIs, respectively. All second tranche CDIs were allotted to investors in November 2018. On June 30, 2019, Crystal Amber converted the 2018 Note to 134,852,549 CDIs (representing 2,697,050 shares of common stock). On June 30, 2019, Crystal Amber converted the March 2019 Note to 81,070,003 CDIs (representing 1,621,400 shares of common stock). On June 30, 2019, Crystal Amber converted the May 2019 Note to 237,687,411 CDIs (representing 4,753,748 shares of common stock). On August 25, 2019, Crystal Amber exercised the 2018 Warrant totaling 97,222,200 CDIs (representing 1,944,444 shares of common stock) and a portion of the March 2019 Warrant totaling 47,244,119 CDIs (equivalent to approximately 944,882 shares of common stock) for an aggregate cash payment of $2 million. On September 30, 2019, Crystal Amber exercised the remaining March 2019 Warrant totaling 31,740,704 CDIs (equivalent to 634,814 shares of common stock) and a portion of the May 2019 Warrant totaling 125,739,610 CDIs (equivalent to 2,514,792 shares of common stock) for an aggregate cash payment of $1.6 million. As of September 30, 2019, this was recorded as common stock – subscribed but unissued and the cash was received on October 1, 2019. On October 31, 2019, Crystal Amber exercised another portion of May 2019 Warrant totaling 78,740,157 CDIs (equivalent to approximately 1,574,803 shares of common stock) for an aggregate cash payment of $1 million. Cash was received on October 31, 2019. On November 15, 2019, Crystal Amber exercised the final portion of May 2019 Warrant totaling 31,740,704 CDIs (equivalent to approximately 634,814 shares of common stock) for an aggregate cash payment of approximately $403 thousand. Cash was received on November 15, 2019.

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement [Text Block]	12. Share-Based Compensation The Company has two stock-based compensation plans. The Board of Directors adopted the 2003 Omnibus Stock Plan (the “2003 Plan”), which provides for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company’s employees, officers, directors, advisors, and outside consultants to purchase up to an aggregate of 922,086 shares of the Company’s common stock. In August 2011, the Board of Directors adopted the 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan”, together with the 2003 Plan, the “Plans”) as the successor to the 2003 Plan. Under the 2011 Plan, the Company may grant incentive stock options, nonqualified stock options, restricted and unrestricted stock awards and other stock-based awards. The Company had initially reserved 450 thousand shares of its common stock for issue under the 2011 Plan. Awards that are returned to the Company’s 2003 Plan as a result of their forfeiture, expiration or cancellation without delivery of common stock shares or that result in the forfeiture of shares back to the Company on or after August 1, 2011, the date the 2011 Plan became effective, are automatically made available for issuance under the 2011 Plan. At August 1, 2011, 80,235 shares available for grant under the 2003 Plan were transferred to the 2011 Plan. As of December 31, 2019, an additional 1,173,917 shares of common stock were made available for grant under the Company’s 2011 Plan. In addition, the 2011 Plan allows for an annual increase in the number of shares available for issue under the 2011 Plan commencing on the first day of each fiscal year during the period beginning in fiscal year 2012 and ending in fiscal year 2020. The annual increase in the number of shares shall be equal to the lowest of: · 500 thousand shares; · 4% of the number of common shares outstanding as of such date; and · an amount determined by the Board of Directors or the Company’s compensation committee. Accordingly, during year ended December 31, 2019, 500 thousand shares were added to the 2011 Plan. During the year ended December 31, 2018, the board of directors elected to not add shares to the 2011 Plan, thereby reserving shares for other purposes. Stock-Based Compensation Stock-based compensation is reflected in the consolidated statements of operations as follows for the years ended December 31, 2019 and 2018 (in thousands): Years Ended 2019 2018 Research and development $ 77 $ 6 Sales and marketing — 23 General and administrative 311 95 $ 388 $ 124 The stock options granted under the Plans generally vest over a four-year period and expire ten years from the date of grant. The weighted-average assumptions used to estimate the fair value of employee stock options using the Black-Scholes option-pricing model were as follows for the years ended December 31, 2019 and 2018: Years Ended 2019 2018 Expected volatility 271.0 % 120.7 % Expected term (in years) 6.05 6.05 Risk-free interest rate 1.8 % 2.6 % Expected dividend yield 0 % 0 % Expected Volatility Volatility measures the amount that a stock price has fluctuated or is expected to fluctuate during a period. As the Company was not publicly traded prior to September 2011 and therefore had no trading history, stock price volatility was estimated based on an analysis of historical and implied volatility of comparable public companies. The Company’s quoted publicly traded CDI price is used as a basis for calculating estimated volatility when there exists adequate history. Expected Term The Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. As a result, for stock option grants made during the years ended December 31, 2019 and 2018, the expected term was estimated using the “simplified method.” The simplified method is based on the average of the contractual term of the option and the weighted-average vesting period of the option. For options granted to non-employees, the Company used the remaining contractual life of the award to estimate the expected term of non-employee awards for the years ended December 31, 2019 and 2018. Risk-Free Interest Rate The risk-free interest rate used for each grant is based on the US Treasury published rate for a zero-coupon U.S. Treasury instrument with a remaining term similar to the expected term of the stock-based award. Expected Dividend Yield The Company has not paid and does not anticipate paying cash dividends on its shares of common stock in the foreseeable future; therefore, the expected dividend yield is assumed to be zero. Stock Options The following table summarizes share-based activity under the Company’s stock option plans: Shares of Weighted- Weighted- Weighted- Aggregate (in years) (in years) (in thousands) Outstanding at December 31, 2018 1,142,883 $ 2.24 $ 2.20 8.48 $ — Granted 1,994,771 $ 1.08 $ 0.23 Exercised — — — Cancelled (41,500 ) $ 0.91 $ 0.91 Outstanding at December 31, 2019 3,096,154 $ 1.47 $ 1.50 8.30 — Vested or expected to vest at December 31, 2019 3,096,154 — Exercisable at December 31, 2019 685,015 $ 2.86 $ 0.04 7.10 $ — The majority of the Company’s option grants vest 25% on the first anniversary of the grant date, and in a quarterly straight-line rate thereafter until fully vested on the fourth anniversary of the grant date. The weighted average grant date fair value for options granted in 2019 and 2018, was $1.04 and $0.97, respectively. The unrecognized stock compensation expense at December 31, 2019 was $2.4 million and was expected to be recognized over a weighted average period of 3.26 years from December 31, 2019. Performance Stock Units Each performance stock unit (“PSU”) represents a contingent right to receive one share of the Company’s common stock. There is no consideration payable on the vesting of PSUs issued under the Plans. Upon vesting, the PSUs are exercised automatically and settled in shares of the Company’s common stock. During the years ended December 31, 2019 and 2018, the Company awarded no PSUs to employees and directors of the Company. Due to the resignation of an employee, one grant of 142,659 PSUs was cancelled in 2018. The following table summarizes information related to PSU activity during the year ended December 31, 2019: Number Weighted- Aggregate (in years) (in thousands) Outstanding at December 31, 2018 250,000 7.23 $ 141 Granted — Exercised — Cancelled — Outstanding at December 31, 2019 250,000 6.23 $ 149 The aggregate intrinsic value at December 31, 2019 noted in the table above represents the closing price of the Company’s common stock multiplied by the number of PSUs outstanding. The fair value of each PSU award equals the closing price of the Company’s common stock on the date of grant. At December 31, 2019, 250,000 of the PSUs outstanding vest on the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company will expense the compensation of the respective stock award over the implicit service period. During the years ended December 31, 2019 and 2018, the Company recognized no stock-based compensation related to performance-based vesting of PSUs. As of December 31, 2019, there was approximately $200 thousand of unrecognized stock-based compensation expense related to non-vested PSU awards that have performance-based vesting. Non-employee awards The Company has recorded non-employee stock-based compensation expense of approximately $26 thousand and $20 thousand during the years ended December 31, 2019 and 2018, respectively, which is included in the total stock-based compensation expense. The unrecognized compensation expense associated with outstanding non-employee grants was $0 and $180 thousand at December 31, 2019 and 2018, respectively. On October 29, 2019, the Company’s Board of Directors approved, subject to stockholder approval per ASX Listing Rule 10.14, the grant of stock options (“NED Options”) conferring the right to purchase up to 30,000 shares of the Company’s common stock to each of the Company’s four non-executive directors pursuant to the Company’s 2011 Plan. The exercise price is $1.34 per share of common stock and the NED Options will vest in full on October 29, 2020 if the individual remains a director of the Company through that date. The NED Options will vest immediately on a change in control event. The NED Options are immediately exercisable, subject to repurchase rights if purchased prior to vesting. The NED Options will be cancelled immediately upon termination of service as a director, unless such termination is the result of a defined change in control event, in which case the NED Options will be cancelled 12 months after such termination. On December 16, 2019, stockholders approved the NED Options.

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	13. Retirement Plans The Company has a 401(k) retirement and savings plan (“401(k) Plan”) covering all qualified U.S. employees. The 401(k) Plan is a defined contribution plan and allows each participant to contribute up to 100% of the participant’s base wages up to an amount not to exceed an annual statutory maximum. The Company has made discretionary contributions to the 401(k) Plan and recorded expenses of approximately $48 and $24 thousand for the years ended December 31, 2019 and 2018, respectively. The Company maintains a defined contribution plan for certain international employees. The Company contributes 100% of the cost of the defined contribution. The Company recorded expenses of approximately $9 and $12 thousand for the years ended December 31, 2019 and 2018, respectively, under this plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes The components of loss before provision for income taxes consisted of the following (in thousands): Years Ended 2019 2018 Domestic $ (17,376 ) $ (8,054 ) Foreign 88 29 Total $ (17,288 ) $ (8,025 ) The components of the provision for income taxes in the accompanying consolidated statements of operations consisted of the following (in thousands): Years Ended 2019 2018 Current Provision: Federal $ — $ — State 1 1 Foreign 42 13 Total current 43 14 Deferred (Benefit) Provision: Federal — — State — — Foreign 2 (1 ) Total deferred 2 (1 ) Total provision $ 45 $ 13 A reconciliation of the provision for income taxes from operations computed using the U.S. federal statutory rate of 21% to that reflected in operations follows (in thousands): Years Ended 2019 2018 Income tax benefit using U.S. federal statutory rate $ (3,624 ) $ (1,675 ) State rate, net of federal benefit (631 ) (438 ) Permanent differences Nondeductible interest 1,052 36 Warrants 353 — GILTI 8 — Meals and entertainment 6 3 Other 2 1 Tax credits generated (147 ) (45 ) Change in valuation allowance 2,888 2,041 Foreign rate differential 4 3 Other items 96 63 Stock compensation 38 24 Total provision $ 45 $ 13 Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 66,859 $ 63,881 Research and development credit carryforwards 4,083 4,026 Capitalized research and development costs — 123 Capitalized start-up expenses 2,133 2,490 Depreciation and other 635 305 Total deferred tax assets 73,710 70,825 Valuation allowance (73,703 ) (70,815 ) Net deferred tax asset $ 7 $ 10 Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of the Company’s deferred tax assets and determined that it is more likely than not that the Company will not recognize the benefits of the deferred tax assets related to the U.S. As a result, a valuation allowance of approximately $73.7 million and $70.8 million was established at December 31, 2019 and 2018, respectively. The valuation allowance increased by approximately $2.9 million during the year ended December 31, 2019, primarily due to the benefit of the current year tax loss. During the year ended December 31, 2019, the Company utilized its remaining carryforward net operating losses in the Netherlands. No valuation allowance is recorded against the net deferred tax assets in Australia related to future tax benefits that will offset future taxable income. At December 31, 2019, the Company had U.S. federal and state net operating loss carryforwards of approximately $248.8 million and $231.1 million, respectively. These operating loss carryforwards will expire at various times beginning in 2024 through 2038 for federal purposes and begin to expire in 2030 and will continue to expire through 2039 for state purposes. Note that the $25.8 million net operating losses incurred in 2018 and 2019 can be carried forward indefinitely for federal purposes. In addition, at December 31, 2019, the Company also has U.S. federal and state research and development tax credit carryforwards (excluding ASC 740, Income Taxes The Company has not yet completed a study of its research and development credit carryforwards. Once completed, this study may result in an adjustment to the Company’s research and development credit carryforwards. A full valuation allowance has been provided against the Company’s research and development credits, and if an adjustment is required at the time the study is completed, this adjustment would be offset by an adjustment to the deferred tax asset established for the research and development credit carryforward and the valuation allowance. Utilization of net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Sections 382 and Section 383 of the Internal Revenue Code of 1986, as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research and development credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change, as defined by IRC Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. The Company has completed several financings since its inception, which may have resulted in a change in control as defined by IRC Section 382 or could result in a change in control in the future. As of December 31, 2019, the Company has not, as yet, conducted an IRC Section 382 study, which could impact its ability to utilize net operating loss and tax credit carryforwards annually in the future to offset the Company’s taxable income, if any. The Company applies ASC 740-10, which provides guidance on the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. At December 31, 2019 and 2018, the Company had unrecognized tax liabilities of approximately $1.5 million and $1.5 million, respectively. The following is a roll forward of the Company’s unrecognized tax benefits (in thousands): December 31, 2019 2018 Unrecognized tax benefit – as of the beginning of the year $ 1,462 $ 1,481 Gross decreases – expiration of underlying tax asset (21 ) (35 ) Gross increases – current period tax positions 39 16 Unrecognized tax benefits – as of the end of the year $ 1,480 $ 1,462 The Company will recognize interest and penalties related to uncertain tax positions, should they be assessed, in income tax expense. As of December 31, 2019, and 2018, the Company had no accrued interest or penalties related to uncertain tax positions, and no amounts have been recognized in the Company’s consolidated statements of operations. The statute of limitations for assessment by the Internal Revenue Service (“IRS”) and state tax authorities is open for tax years ended December 31, 2016 through December 31, 2019, although carryforward attributes that were generated prior to tax year 2016 may still be adjusted upon examination by the IRS or state tax authorities if they either have been or will be used in a future period. The statute of limitations for assessment by foreign tax authorities is open for tax years ended December 31, 2015 through December 31, 2019. There are currently no foreign, federal or state audits in progress.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. Subsequent Events On January 13, 2020, GI Dynamics received approximately $4.6 million pursuant to the August 2019 Note. On receipt of funds, the August 2019 Note became convertible per the August 2019 Note terms (see Note 9), and GI Dynamics issued the August 2019 Warrant (see Notes 4 and 9). On March 11, 2020, the World Health Organization declared the outbreak of a coronavirus (COVID-19) a pandemic. As a result, economic uncertainties have arisen which are likely to negatively impact GI Dynamics short term-operations, for example in delays in timing of regulatory audits and in facing enrollment pauses in clinical trials. If the impacts are limited in duration, the Company anticipates an ability to overcome delays and return to original timing estimates, but there can be no guarantee the impacts will be limited to the degree required. Additionally, market-level impacts may affect the timing or the negotiation of terms in the Company’s financing efforts. Other financial impacts could occur though such potential impact is unknown at this time.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GI Dynamics, Inc. and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation. The functional currency of GID Europe Holding B.V., GID Europe B.V., GID Germany GmbH and GI Dynamics Australia Pty Ltd is the U.S. dollar. Consolidated balance sheet accounts of the Company’s subsidiaries are remeasured into U.S. dollars using the exchange rate in effect at the consolidated balance sheet date while expenses are remeasured using the average exchange rate in effect during the period. Gains and losses arising from remeasurement of the wholly owned subsidiaries’ financial statements are included in the determination of net loss.
Segment Reporting	Segment Reporting The Company has one reportable segment which designs, develops, manufactures and markets medical devices for non-surgical approaches to treating type 2 diabetes. GI Dynamics does not report geographic segments as there were no product sales in 2019 or 2018 and at December 31, 2019 and 2018, all long-lived assets comprised of property and equipment were held in the U.S.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the U.S. requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, inventory valuation including reserves for excess and obsolete inventory, impairment of long-lived assets, income taxes including the valuation allowance for deferred tax assets, research and development, contingencies, valuation of warrant and other derivative liabilities, estimates used to assess its ability to continue as a going concern and stock-based compensation. GI Dynamics bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash GI Dynamics considers all highly liquid investment instruments with an original maturity when purchased of three months or less to be cash equivalents. Investments qualifying as cash equivalents primarily consist of money market funds and have a carrying amount that approximates fair value. The amount of cash equivalents included in cash and cash equivalents was approximately $0 and $1.1 million at December 31, 2019 and 2018, respectively. At December 31, 2019 and 2018, GI Dynamics had approximately $2 and $0.01 million, respectively, of cash and cash equivalents denominated in Australian dollars or Euros that is subject to foreign currency gain and loss. GI Dynamics has $30 thousand in restricted cash used to secure a corporate credit card account.
Property and Equipment	Property and Equipment Property and equipment, are recorded at cost and are depreciated when placed in service using the straight-line method based on their estimated useful lives as follows: Asset Description Estimated (In Years) Laboratory and manufacturing equipment 5 Computer equipment and software 3 Office furniture and equipment 5 Included in property and equipment are certain costs of software obtained for internal use. Costs incurred during the preliminary project stage are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized over the estimated useful life of the software. GI Dynamics also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional functionality. Maintenance and training costs related to software obtained for internal use are expensed as incurred. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining lease term. Costs for capital assets not yet placed into service have been capitalized as construction in progress and will be depreciated in accordance with the above guidelines once placed into service. Maintenance and repair costs are expensed as incurred.
Derivative Liabilities	Derivative Liabilities GI Dynamics examines all financial instruments to determine if the financial instrument or any component feature is a derivative under ASC 815, Derivatives and Hedging
Research and Development Costs	Research and Development Costs Research and development costs are expensed when incurred. Research and development costs include costs of all basic research activities as well as other research, engineering, and technical effort required to develop a new product or service or make significant improvement to an existing product or manufacturing process. Research and development costs also include preapproval regulatory and clinical trial expenses.
Patent Costs	Patent Costs GI Dynamics expenses as incurred all costs, including legal expenses, associated with obtaining patents until the patented technology becomes feasible. All costs incurred after the patented technology is feasible will be capitalized as an intangible asset. As of December 31, 2019, no such costs had been capitalized since inception of the Company. GI Dynamics has expensed approximately $200 thousand of patent costs within general and administrative expenses in the consolidated statements of operations for each of the years ended December 31, 2019 and 2018.
Stock-Based Compensation	Stock-Based Compensation GI Dynamics accounts for stock-based compensation in accordance with the Financial Accounting Standards Board, (“FASB”) Accounting Standards Codification (“ASC”) 718, Stock Compensation For awards that vest based on service conditions, GI Dynamics uses the straight-line method to allocate compensation expense to reporting periods. The grant date fair value of options granted is calculated using the Black-Scholes option pricing model, which requires the use of subjective assumptions including volatility, expected term and the fair value of the underlying common stock, among others. The assumptions used in determining the fair value of stock-based awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change, and management uses different assumptions, the Company’s stock-based compensation could be materially different in the future. The risk-free interest rate used for each grant is based on a zero-coupon U.S. Treasury instrument with a remaining term similar to the expected term of the stock-based award. Because GI Dynamics does not have a sufficient stable history to estimate the expected term, it uses the simplified method for estimating the expected term. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. Because there was no public market for GI Dynamics common stock prior to its IPO, GI Dynamics lacked company-specific historical and implied volatility information. The Company does have approximately 6 years of historical price volatility since its IPO in September 2011. Therefore, management estimates the expected stock volatility based on the to-date historical price volatility. GI Dynamics has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero. GI Dynamics recognizes the impact of share-based award forfeitures only as they occur rather than by applying an estimated forfeiture rate. GI Dynamics periodically issues performance-based awards. For these awards, vesting will occur upon the achievement of certain milestones. When achievement of the milestone is deemed probable, the Company records as compensation expense, the value of the respective stock award over the implicit remaining service period. Stock awards to non-employees were accounted for in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). The measurement date for non-employee awards was generally the date performance of services required from the non-employee was complete. For non-employee awards that vest based on service conditions, the Company expensed the value of the awards over the related service period, provided the service condition was expected to be met. The Company recorded the expense of services rendered by non- employees based on the estimated fair value of the stock option using the Black-Scholes option pricing model over the contractual term of the non-employee award. At each reporting period, the fair value of unvested non-employee awards was remeasured and expensed on a straight-line basis over the vesting term of the underlying award. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718: Improvements to nonemployee share-based payment accounting)
New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update, or ASU No. 2016-02, Leases In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718: Improvements to nonemployee share-based payment accounting) Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820), Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets GI Dynamics regularly reviews the carrying amount of its long-lived assets to determine whether indicators of impairment may exist that merit adjustments to carrying values or estimated useful lives. If indications of impairment exist, projected future undiscounted cash flows associated with the asset are compared to the carrying amount to determine whether the asset’s value is recoverable. If the carrying value of the asset exceeds such projected undiscounted cash flows, the asset will be written down to its estimated fair value. No such impairments were recorded in 2019 or 2018.
Loss Contingencies	Loss Contingencies In accordance with ASC 450, Contingencies
Fraudulent Diversion of Funds and Related Insurance Proceeds	Fraudulent Diversion of Funds and Related Insurance Proceeds In July 2018, after a third-party investigation isolated the activity, an insurance claim was filed for $271 thousand for fraudulent diversion of cash from the Company’s account into a personal account that occurred during the years 2016 through 2018. Income in the year ended December 31, 2018 represents net insurance proceeds on the claim less $22 thousand of research and development expense. GI Dynamics has since implemented internal controls to correct the identified control deficiencies associated with the fraud and the employee responsible for the diverted funds is no longer with the Company.
Income Taxes	Income Taxes GI Dynamics uses the asset and liability method of accounting for income taxes. The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between its financial reporting and the tax bases of assets and liabilities measured using the enacted tax rates in effect in the years in which the differences are expected to reverse. The Company regularly assesses the need for a valuation allowance against its deferred tax assets. Future realization of the Company’s deferred tax assets ultimately depends on the existence of sufficient taxable income within the available carryback or carryforward periods. Sources of taxable income include taxable income in prior carryback years, future reversals of existing taxable temporary differences, tax planning strategies, and future taxable income. The Company records a valuation allowance to reduce its deferred tax assets to an amount it believes is more-likely-than-not to be realized. Deferred tax assets are reduced by a valuation allowance to reflect the uncertainty associated with their ultimate realization. The Company assesses its income tax positions and records tax benefits based upon management’s evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions where it is more-likely-than-not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more-likely-than-not that a tax benefit will be sustained, no tax benefit is recognized in the financial statements. The Company classifies interest and penalties on uncertain tax positions as income tax expense.
Guarantees	Guarantees GI Dynamics has identified the guarantees described below as disclosable, in accordance with ASC 460, Guarantees As permitted under Delaware law, GI Dynamics indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company maintains directors’ and officers’ insurance coverage that should limit its exposure and enable it to recover a portion of any future amounts paid. GI Dynamics is a party to a number of agreements entered into in the ordinary course of business that contain typical provisions that obligate it to indemnify the other parties to such agreements upon the occurrence of certain events. Such indemnification obligations are usually in effect from the date of execution of the applicable agreement for a period equal to the applicable statute of limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of December 31, 2019, and 2018, GI Dynamics had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible. As a result, no related reserves have been established.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Public Utility Property, Plant, and Equipment [Table Text Block]	Asset Description Estimated (In Years) Laboratory and manufacturing equipment 5 Computer equipment and software 3 Office furniture and equipment 5

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Years Ended December 31, 2019 2018 Warrants to purchase common stock 28,532 1,972,976 Options to purchase common stock and other stock-based awards 3,331,154 1,545,719 Total 3,359,686 3,518,695

Warrants to Purchase Common S_2

Warrants to Purchase Common Stock or CDIs (Tables)	12 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of warrants outstanding and exercisable [Table Text Block]	Number of underlying Exercise price December 31, Warrant Series Issue Date shares per share 2019 2018 Consultant warrant May 4, 2016 28,532 $ 0.64 28,532 28,532 2018 Warrant (1) May 24, 2018 1,944,444 $ 0.72 - 1,944,444 Total Outstanding and Exercisable 28,532 1,972,976 Weighted average exercise price $ 0.64 $ 0.72 (1) Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Shares underlying warrants Weighted average exercise price per share Outstanding and Exercisable at December 31, 2018 1,972,976 $ 0.72 Issuance of March 2019 Warrant 1,579,696 $ 0.64 Issuance of May 2019 Warrant 4,724,409 $ 0.64 Exercise of 2018 Warrant (1,944,444 ) $ 0.72 Exercise of March 2019 Warrant (1,579,696 ) $ 0.64 Exercise of May 2019 Warrant (4,724,409 ) $ 0.64 Outstanding and Exercisable at December 31, 2019 28,532 $ 0.64

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using Quoted Prices Significant in Active Other Significant December 31, Identical Assets Inputs Inputs Description 2019 (Level 1) (Level 2) (Level 3) Liabilities Warrant liability $ 10 $ — $ — $ 10 Total liabilities $ 10 $ — $ — $ 10 Fair Value Measurements at Reporting Date Using Quoted Prices Significant in Active Other Significant December 31, Identical Assets Inputs Inputs Description 2018 (Level 1) (Level 2) (Level 3) Assets Money market funds (included in cash and cash equivalents) $ 1,097 $ 1,097 $ — $ — Total assets $ 1,097 $ 1,097 $ — $ — Liabilities Warrant liability $ 51 $ — $ — $ 51 Total liabilities $ 51 $ — $ — $ 51
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	December 31, 2019 2018 Expected volatility 130.0 % 134.0 % Expected term (in years) 1.35 2.35 Risk-free interest rate 1.59 % 2.48 % Expected dividend yield — % — % March 2019 Warrants May 2019 Warrants March 15, March 31, June 28, May 8, June 28, 2019 2019 2019 2019 2019 Expected volatility 130.7 % 131.2 % 134.0 % 134.0 % 137.3 % Expected term (in years) 5.00 4.97 2.35 5.00 4.87 Risk-free interest rate 2.44 % 2.34 % 1.74 % 2.28 % 1.74 % Expected dividend yield — % — % — % — % — %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Balance at December 31, 2017 $ 493 Decrease in fair value of 2017 Note-related conversion feature upon re-measurement (464 ) Decrease in fair value of warrants upon re-measurement (18 ) Fair value of beneficial conversion feature discount associated with 2017 Note modification 40 Balance at December 31, 2018 $ 51 Increase in fair value of warrants upon re-measurement 1,683 Fair value of warrants issued with notes to related party 4,061 Reclassification of warrants to additional paid-in capital (5,785 ) Balance at December 31, 2019 $ 10

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	December 31, 2019 2018 Laboratory and manufacturing equipment $ 591 $ 591 Computer equipment and software 1,193 1,182 Office furniture and equipment 183 183 1,967 1,956 Less accumulated depreciation and amortization (1,925 ) (1,893 ) Total $ 42 $ 63

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	December 31, 2019 2018 Payroll and related liabilities $ 531 $ 386 Professional fees 335 573 Credit refunds 164 186 Interest payable 250 495 Other 73 5 Total $ 1,353 $ 1,645

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Lease, Cost [Table Text Block]	December 31, 2019 (in thousands) Operating cash flows from operating leases in lease liability measurement $ 148 Operating cash flows from short term leases 103 Remaining long-term lease term in years 2.4 Discount rate 10 %
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	December 31, 2019 (in thousands) 2020 178 2021 182 2022 76 Total future minimum lease payments 436 Less: imputed interest (50 ) Total liabilities $ 386

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Years Ended 2019 2018 Research and development $ 77 $ 6 Sales and marketing — 23 General and administrative 311 95 $ 388 $ 124
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Years Ended 2019 2018 Expected volatility 271.0 % 120.7 % Expected term (in years) 6.05 6.05 Risk-free interest rate 1.8 % 2.6 % Expected dividend yield 0 % 0 %
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares of Weighted- Weighted- Weighted- Aggregate (in years) (in years) (in thousands) Outstanding at December 31, 2018 1,142,883 $ 2.24 $ 2.20 8.48 $ — Granted 1,994,771 $ 1.08 $ 0.23 Exercised — — — Cancelled (41,500 ) $ 0.91 $ 0.91 Outstanding at December 31, 2019 3,096,154 $ 1.47 $ 1.50 8.30 — Vested or expected to vest at December 31, 2019 3,096,154 — Exercisable at December 31, 2019 685,015 $ 2.86 $ 0.04 7.10 $ —
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Number Weighted- Aggregate (in years) (in thousands) Outstanding at December 31, 2018 250,000 7.23 $ 141 Granted — Exercised — Cancelled — Outstanding at December 31, 2019 250,000 6.23 $ 149

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Years Ended 2019 2018 Domestic $ (17,376 ) $ (8,054 ) Foreign 88 29 Total $ (17,288 ) $ (8,025 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years Ended 2019 2018 Current Provision: Federal $ — $ — State 1 1 Foreign 42 13 Total current 43 14 Deferred (Benefit) Provision: Federal — — State — — Foreign 2 (1 ) Total deferred 2 (1 ) Total provision $ 45 $ 13
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Years Ended 2019 2018 Income tax benefit using U.S. federal statutory rate $ (3,624 ) $ (1,675 ) State rate, net of federal benefit (631 ) (438 ) Permanent differences Nondeductible interest 1,052 36 Warrants 353 — GILTI 8 — Meals and entertainment 6 3 Other 2 1 Tax credits generated (147 ) (45 ) Change in valuation allowance 2,888 2,041 Foreign rate differential 4 3 Other items 96 63 Stock compensation 38 24 Total provision $ 45 $ 13
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 66,859 $ 63,881 Research and development credit carryforwards 4,083 4,026 Capitalized research and development costs — 123 Capitalized start-up expenses 2,133 2,490 Depreciation and other 635 305 Total deferred tax assets 73,710 70,825 Valuation allowance (73,703 ) (70,815 ) Net deferred tax asset $ 7 $ 10
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	December 31, 2019 2018 Unrecognized tax benefit – as of the beginning of the year $ 1,462 $ 1,481 Gross decreases – expiration of underlying tax asset (21 ) (35 ) Gross increases – current period tax positions 39 16 Unrecognized tax benefits – as of the end of the year $ 1,480 $ 1,462

Nature of Business (Details)

Nature of Business (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Nature of Business (Details) [Line Items]
Types of diabetes population, description	Diabetes mellitus type 2 (also known as type 2 diabetes) is a long-term progressive metabolic disorder characterized by high blood sugar, insulin resistance, and reduced insulin production. People with type 2 diabetes represent 90-95% of the worldwide diabetes population; only 5-10% of this population is diagnosed with type 1 diabetes (a form of diabetes mellitus wherein little to no insulin is produced).
Number of reportable segments	1
Accumulated deficit	$ (284,492)	$ (267,159)
Working capital deficit	3,400
Cash and cash equivalents, restricted cash	$ 2,529	$ 3,836	$ 3,064
Type 2 Diabetes [Member]
Nature of Business (Details) [Line Items]
Types of diabetes population, description	Fewer than 50% of patients treated pharmacologically for type 2 diabetes are adequately managed, meaning that medication does not lower blood sugar adequately and does not halt the progressive nature of diabetes of these patients.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Basis of Presentation (Details) € in Thousands, $ in Thousands, $ in Millions	1 Months Ended	12 Months Ended
	Jul. 31, 2018USD ($)	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2019AUD ($)	Dec. 31, 2019EUR (€)
Summary of Significant Accounting Policies and Basis of Presentation (Details) [Line Items]
Number of Reportable Segments		1
Cash and cash equivalents		$ 2,499	$ 3,806
Restricted cash		30	30
General and administrative expenses		$ 5,295	4,809
Term of historical price volatility		6 years
Expected dividend yield		0.00%
Insurance claim for fraudulent activity	$ 271
Net insurance proceeds on claim less research and development expense			22
Options to purchase shares of common stock granted to non-employees (in Shares) | shares		120,000
Patents [Member]
Summary of Significant Accounting Policies and Basis of Presentation (Details) [Line Items]
General and administrative expenses		$ 200
Cash and Cash Equivalents [Member]
Summary of Significant Accounting Policies and Basis of Presentation (Details) [Line Items]
Cash and cash equivalents		$ 0	$ 1,100	$ 2	€ 10

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Basis of Presentation (Details) - Schedule of property and equipment useful lives	12 Months Ended
	Dec. 31, 2019
Laboratory and manufacturing equipment [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	5 years
Computer equipment and software [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	3 years
Office furniture and equipment [Member]
Public Utility, Property, Plant and Equipment [Line Items]
Estimated useful life (in years)	5 years

Net Loss per Common Share (Deta

Net Loss per Common Share (Details) - Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	3,359,686	3,518,695
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	28,532	1,972,976
Options to purchase common stock and other stock-based awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted weighted-average shares outstanding	3,331,154	1,545,719

Warrants to Purchase Common S_3

Warrants to Purchase Common Stock or CDIs (Details) - $ / shares	1 Months Ended
	Aug. 21, 2109	Nov. 30, 2018	May 24, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Exercise price per share		$ 0.72	$ 0.90
Warrants description	On August 21, 2019, GI Dynamics and Crystal Amber entered into a securities purchase agreement (“SPA”) for a total funding of up to approximately $10 million (the “August 2019 SPA”) comprised of the scheduled exercise of the 2018 Warrant, the March 2019 Warrant, and the May 2019 Warrant as detailed above and the sale of an Unsecured Convertible Note for up to approximately $4.6 million (the “August 2019 Note”), which included an agreement to issue a warrant (the “August 2019 Warrant”) to purchase up to 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI.

Warrants to Purchase Common S_4

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable - $ / shares		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Nov. 30, 2018	May 24, 2018
Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Number of underlying shares		28,532	1,972,976
Exercise price per share (in Dollars per share)				$ 0.72	$ 0.90
Total Outstanding and Exercisable		28,532	1,972,976
Weighted average exercise price (in Dollars per share)		$ 0.64	$ 0.72
Consultant Warrant [Member]
Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Issue Date		May 4, 2016
Number of underlying shares		28,532
Exercise price per share (in Dollars per share)		$ 0.64
Total Outstanding and Exercisable		28,532	28,532
2018 Warrant [Member]
Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrants outstanding and exercisable [Line Items]
Issue Date	[1]	May 24, 2018
Number of underlying shares	[1]	1,944,444
Exercise price per share (in Dollars per share)	[1]	$ 0.72
Total Outstanding and Exercisable	[1]		1,944,444
[1]	Exercise price was initially $0.90 per share, but was adjusted to $0.72 in November 2018

Warrants to Purchase Common S_5

Warrants to Purchase Common Stock or CDIs (Details) - Schedule of warrant activity - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Class of Warrant or Right [Line Items]
Shares underlying warrants	28,532	1,972,976
Weighted average exercise price per share	$ 0.64	$ 0.72
Issuance of March 2019 Warrant [Member]
Class of Warrant or Right [Line Items]
Shares underlying warrants	1,579,696
Weighted average exercise price per share	$ 0.64
Issuance of May 2019 Warrant [Member]
Class of Warrant or Right [Line Items]
Shares underlying warrants	4,724,409
Weighted average exercise price per share	$ 0.64
Exercise of 2018 Warrant [Member]
Class of Warrant or Right [Line Items]
Shares underlying warrants	(1,944,444)
Weighted average exercise price per share	$ 0.72
Exercise of March 2019 Warrant [Member]
Class of Warrant or Right [Line Items]
Shares underlying warrants	(1,579,696)
Weighted average exercise price per share	$ 0.64
Exercise of May 2019 Warrant [Member]
Class of Warrant or Right [Line Items]
Shares underlying warrants	(4,724,409)
Weighted average exercise price per share	$ 0.64

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of fair value of assets and liabilities measured on recurring basis - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Liabilities
Warrant liability	$ 10	$ 51
Total liabilities	10	51
Assets
Money market funds (included in cash and cash equivalents)		1,097
Total assets		1,097
Fair Value, Inputs, Level 1 [Member]
Liabilities
Warrant liability
Total liabilities
Assets
Money market funds (included in cash and cash equivalents)		1,097
Total assets		1,097
Fair Value, Inputs, Level 2 [Member]
Liabilities
Warrant liability
Total liabilities
Assets
Money market funds (included in cash and cash equivalents)
Total assets
Fair Value, Inputs, Level 3 [Member]
Liabilities
Warrant liability	10	51
Total liabilities	$ 10	51
Assets
Money market funds (included in cash and cash equivalents)
Total assets

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of black-scholes option pricing model to determine the fair value of the Derivative Warrant Liabilities	6 Months Ended
	Dec. 31, 2019	Jun. 28, 2019	May 08, 2019	Mar. 31, 2019	Mar. 15, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected volatility	130.00%					134.00%
Expected term (in years)	1 year 127 days					2 years 127 days
Risk-free interest rate	1.59%					2.48%
Expected dividend yield
March 2019 Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected volatility		134.00%		131.20%	130.70%
Expected term (in years)		2 years 127 days		4 years 354 days	5 years
Risk-free interest rate		1.74%		2.34%	2.44%
Expected dividend yield
May 2019 Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected volatility		137.30%	134.00%
Expected term (in years)		4 years 317 days	5 years
Risk-free interest rate		1.74%	2.28%
Expected dividend yield

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - Schedule of fair value of derivative liabilities - Derivative Financial Instruments, Liabilities [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance		$ 493
Decrease in fair value of 2017 Note-related conversion feature upon re-measurement		(464)
Decrease in fair value of warrants upon re-measurement		(18)
Fair value of beneficial conversion feature discount associated with 2017 Note modification		40
Balance		$ 51
Increase in fair value of warrants upon re-measurement	$ 1,683
Fair value of warrants issued with notes to related party	4,061
Reclassification of warrants to additional paid-in capital	(5,785)
Balance	$ 10

Concentrations of Credit Risk_2

Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Concentrations of Credit Risk, Accounts Receivable and Related Valuation Account [Abstract]
Allowance for doubtful accounts balance	$ 0	$ 40

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Apr. 13, 2018	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Loss on disposal of leasehold improvements	$ 2		$ 2
Depreciation and amortization expense		$ 32	$ 35

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 1,967	$ 1,956
Less accumulated depreciation and amortization	(1,925)	(1,893)
Total	42	63
Laboratory and manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	591	591
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	1,193	1,182
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross	$ 183	$ 183

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	1 Months Ended
	Dec. 31, 2107	Dec. 31, 2018
Accrued Expenses (Details) [Line Items]
Accrued expenses, description	the Company notified its customers to return their inventory on hand. The Company calculated an estimate for returns, reversed its revenue and recorded an accrued expense estimate of $202 thousand of product return related costs in addition to $77 thousand of credit memos granted to customers.
2017 Note [Member]
Accrued Expenses (Details) [Line Items]
Interest payable	$ 136	$ 394
2017 and 2018 Notes [Member]
Accrued Expenses (Details) [Line Items]
Interest payable		$ 359

Accrued Expenses (Details) - Sc

Accrued Expenses (Details) - Schedule of accrued expenses - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule of accrued expenses [Abstract]
Payroll and related liabilities	$ 531	$ 386
Professional fees	335	573
Credit refunds	164	186
Interest payable	250	495
Other	73	5
Total	$ 1,353	$ 1,645

Notes Payable (Details)

Notes Payable (Details) - USD ($) $ / shares in Units, $ in Thousands

Jan. 13, 2020

Nov. 15, 2019

May 08, 2019

Mar. 15, 2019

Oct. 31, 2019

Sep. 30, 2019

Aug. 31, 2019

Aug. 25, 2019

Jun. 30, 2019

May 30, 2018

Jun. 15, 2017

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Dec. 06, 2019

Nov. 30, 2018

May 24, 2018

Notes Payable (Details) [Line Items]

Principle amount

$ 4,600

$ 4,600

Unpaid interest

10.00%

8.00%

Exercise price per share (in Dollars per share)

$ 0.72

$ 0.90

Debt instrument, convertible, beneficial conversion feature

$ 1,007

Accrued interest expense

$ 250

495

Extinguishment of Debt, Nature of Restrictions on Assets Set Aside for Scheduled Payments

$1.6

$1

Conversion price (in Dollars per share)

$ 0.02

Unpaid interest

110.00%

2018 Warrant [Member]

Notes Payable (Details) [Line Items]

Estimated fair value of warrant

$ 743

March 2019 Warrant [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 623

Interest rate during period

110.00%

Estimated fair value of warrant

$ 850

Debt instrument, convertible, beneficial conversion feature

129

Debt value

129

Re-measurement of derivative liabilities

576

Fair value of warrants from derivative liability to equity

$ 1,400

Interest rate note for discount

29.40%

May 2019 Warrant [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

236,220,472

Chess Deposit Interest [Member] | 2018 Warrant [Member]

Notes Payable (Details) [Line Items]

Class of warrant exercise price adjustment (in Dollars per share)

$ 0.0144

Warrant to purchase CDIs (in Shares)

97,222,200

Exercise price per share (in Dollars per share)

$ 0.018

Warrant exercised

$ 1,400

Chess Deposit Interest [Member] | March 2019 Warrant [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

78,984,823

Exercise price per share (in Dollars per share)

$ 0.0127

2018 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Interest expenses

$ 91

102

Amortization of the issuance costs

85

Debt instrument, convertible, beneficial conversion feature

$ 1,200

Debt instrument, effective interest rate

26.40%

Amortization of debt discount

$ 146

168

2018 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Debt instrument conversion description

the entire outstanding principal balance under the 2018 Note and all unpaid accrued interest thereon was immediately convertible into CDIs, at the option of Crystal Amber at an initial conversion price of $0.018 per CDI. Subsequently, the Company issued additional CDIs in an equity financing in September 2018 at a price per CDI of $0.0144, resulting in an adjustment of the conversion price to $0.0144 per CDI. Notice to convert the 2018 Note was provided by Crystal Amber, a Related Party on June 30, 2019. The 2018 Note converted to 134,852,549 CDIs (representing 2,697,050 shares of common stock).

Debt instrument conversion price per CDI (in Dollars per share)

$ 0.018

2018 Warrant [Member]

Notes Payable (Details) [Line Items]

Class of warrant exercise price adjustment (in Dollars per share)

$ 0.0144

2018 Senior Unsecured Convertible Promissory Note and Warrant [Member]

Notes Payable (Details) [Line Items]

Debt instrument conversion description

The principal of approximately $1.8 million converted to 121,527,778 CDIs (representing 2,430,555 shares of common stock) and the accrued interest of $192 thousand converted to 13,324,772 CDIs (representing 266,495 shares of common stock). As of June 30, 2019, the conversion of the CDIs had been executed, but not yet settled with the CDIs issued and available. The CDIs were issued on July 3, 2019 and have a one-year restriction on trading on the ASX.

Debt instrument, convertible, beneficial conversion feature

1,000

March 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 1,000

Interest rate during period

10.00%

Debt issuance costs

$ 50

Maturity date

Mar. 15, 2024

Warrant exercised (in Dollars per share)

$ 400,000

March 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Exercise price per share (in Dollars per share)

$ 0.0127

Warrant exercised

$ 600

Conversion of notes into shares (in Shares)

81,070,003

2019 Senior Unsecured Convertible Promissory Note and Warrant [Member]

Notes Payable (Details) [Line Items]

Debt instrument, convertible, beneficial conversion feature

1,000

May 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 3,000

$ 2,000

Interest rate during period

10.00%

Unpaid interest

110.00%

Accrued interest expense

$ 34

Fair value of warrants from derivative liability to equity

$ 3,200

Fair value of warrants from derivative liability to equity

$3

Derivative loss

$ 200

May 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Debt instrument conversion description

After the Company obtained stockholder approval to enable Crystal Amber’s, a Related Party, conversion rights under the May 2019 Note on June 30, 2019, the entire outstanding principal balance under the May 2019 Note and all unpaid accrued interest thereon was convertible into CDIs, at the option of Crystal Amber at a conversion price of $0.0127 per CDI. On June 30, 2019, Crystal Amber elected to convert the May 2019 Note into 237,687,411 CDIs (representing 4,753,748 shares of common stock). The principal of $3.0 million converted to 236,220,472 CDIs (representing 4,724,409 shares of common stock) and the accrued interest of approximately $19 thousand converted to 1,466,939 CDIs (representing 29,339 shares of common stock). As of June 30, 2019, notice of the conversion had been provided by Crystal Amber and the CDIs were issued on July 3, 2019 and have a one-year restriction on trading on the ASX.

May 2019 Warrant [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 403

$ 1,600

Re-measurement of derivative liabilities

$ 1,100

Fair value of warrants from derivative liability to equity

$ 4,300

Interest rate note for discount

29.40%

Total Debt Discount Of Warrants

$ 3,000

Common Stock [Member] | Chess Deposit Interest [Member] | 2018 Warrant [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

1,944,444

Common Stock [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

1,579,696

Conversion of notes into shares (in Shares)

1,621,400

944,882

Common Stock [Member] | May 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

4,724,409

Common Stock [Member] | May 2019 Warrant [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

634,814

1,574,803

2,514,792

2017 Senior Secured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 5,000

Interest rate during period

5.00%

Debt issuance costs

$ 115

Interest expenses

$ 248

257

Amortization of the issuance costs

43

$ 0

2017 Senior Secured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Debt instrument conversion description

Subsequently, the entire outstanding principal balance under the 2017 Note and all unpaid accrued interest thereon is convertible into CDIs (i) prior to the maturity date, at the option of Crystal Amber at a conversion price calculated based on the five-day volume weighted average price of the Company’s CDIs traded on the ASX (“Optional Conversion Price”), or (ii) automatically upon the occurrence of an equity financing in which the Company raises at least $10 million (a “Qualified Financing”) at the price per CDI of the CDIs issued and sold in such financing.

Qualified financing least amount raised

$ 10,000

Percentage of remaining outstanding unconverted principal payment obligation upon change of control

110.00%

2017 Note [Member]

Notes Payable (Details) [Line Items]

Debt issuance costs

$ 5,000

Maturity date

Mar. 31, 2019

Accrued interest

$ 394

2018 Senior Unsecured Convertible Promissory Note and Warrant [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 1,800

Maturity date

May 30, 2023

2018 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Interest rate during period

10.00%

2018 Warrant [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Class of warrant exercise price adjustment (in Dollars per share)

$ 0.0144

Subsequent Event [Member]

Notes Payable (Details) [Line Items]

Debt instrument conversion description

On January 13, 2020, the full amount of approximately $4.6 million was received as proceeds from the August 2019 Note. On receipt of funds, the August 2019 Note conversion feature was immediately available to Crystal Amber. On January 13, 2020, GI Dynamics issued to Crystal Amber the August 2019 Warrant to purchase 229,844,650 CDIs (representing 4,596,893 shares of common stock) for an exercise price of $0.02 per CDI (see Note 4).

Beneficial Conversion Feature [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Accrued interest expense

30

Debt discount

$ 1,000

Tranche One [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

78,740,157

Converted notes with aggregate principal amount

$ 1,000

Tranche One [Member] | May 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Exercise price per share (in Dollars per share)

$ 0.0127

Tranche One [Member] | Common Stock [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

1,574,803

Tranche Two [Member] | May 2019 Warrant [Member]

Notes Payable (Details) [Line Items]

Principle amount

$ 3,000

Accrued interest expense

$ 19

Tranche Two [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

2,329,846

47,244,119

Accrued interest expense

$ 30

Tranche Two [Member] | May 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

125,739,610

Tranche Two [Member] | Common Stock [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

46,597

Tranche Two [Member] | Common Stock [Member] | May 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

2,514,792

Tranche Three [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

31,740,704

Tranche Three [Member] | May 2019 Senior Unsecured Convertible Promissory Note [Member] | Chess Deposit Interest [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

78,740,157

Tranche Three [Member] | Common Stock [Member] | March 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Conversion of notes into shares (in Shares)

634,814

Tranche Three [Member] | Common Stock [Member] | May 2019 Senior Unsecured Convertible Promissory Note [Member]

Notes Payable (Details) [Line Items]

Warrant to purchase CDIs (in Shares)

1,574,803

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Apr. 22, 2019USD ($)m²	Jun. 30, 2016USD ($)m²	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)m²
Commitments and Contingencies Disclosure [Abstract]
Rentable area of leased premises (in Square Meters) | m²	3,520	4,200		985
Operating lease term		The lease commenced in June 2016 and expired in April 2018.		The committed lease term expired in May 2019 and contained a two-month cancellation provision.
Rent expense		$ 12	$ 200	$ 100
Lease obligations				$ 91
Present value of the lease liability in short-term and long-term liabilities and recorded a related right-of-use asset	$ 463
Incremental borrowing rate as discount rate to measure operating lease liabilities			10.00%
Operating Lease, Expense			$ 102
Operating Leases, Rent Expense			7
Other Tax Expense (Benefit)			$ 3

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of other information related to leases $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Schedule of other information related to leases [Abstract]
Operating cash flows from operating leases in lease liability measurement	$ 148
Operating cash flows from short term leases	$ 103
Remaining long-term lease term in years	2 years 146 days
Discount rate	10.00%

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of maturity of operating lease liability $ in Thousands	Dec. 31, 2019USD ($)
Schedule of maturity of operating lease liability [Abstract]
2020	$ 178
2021	182
2022	76
Total future minimum lease payments	436
Less: imputed interest	(50)
Total liabilities	$ 386

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) $ / shares in Units, $ in Thousands

Nov. 15, 2019USD ($)shares

Oct. 31, 2019USD ($)shares

Sep. 30, 2019USD ($)shares

Aug. 25, 2019USD ($)shares

Jun. 30, 2019shares

Oct. 29, 2018USD ($)shares

Sep. 20, 2018USD ($)shares

Feb. 27, 2018USD ($)shares

Jan. 22, 2018USD ($)shares

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2019shares

Dec. 19, 2019shares

Dec. 06, 2019USD ($)

Aug. 31, 2019USD ($)

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized

50,000,000

75,000,000

Capital stock, shares authorized

75,500,000

Preferred stock, shares authorized

500,000

Aggregate cash payment (in Dollars) | $

$ 4,600

$ 4,600

Minimum [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized

50,000,000

Maximum [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock, shares authorized

75,000,000

March 2019 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Aggregate cash payment (in Dollars) | $

$ 1,000

$ 2,000

May 2019 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Aggregate cash payment (in Dollars) | $

$ 403

$ 1,600

Common Stock [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

8,120,056

Common Stock [Member] | 2018 Note [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

2,697,050

Common Stock [Member] | March 2019 Note [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

1,621,400

Common Stock [Member] | May 2019 Note [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

4,753,748

Common Stock [Member] | 2018 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

1,944,444

Common Stock [Member] | March 2019 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

634,814

944,882

Common Stock [Member] | May 2019 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

634,814

1,574,803

2,514,792

Chess Depositary Interests [Member] | 2018 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

97,222,200

Chess Depositary Interests [Member] | 2018 Note [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

134,852,549

Chess Depositary Interests [Member] | March 2019 Note [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

81,070,003

Chess Depositary Interests [Member] | May 2019 Note [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

237,687,411

Chess Depositary Interests [Member] | March 2019 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

31,740,704

47,244,119

Chess Depositary Interests [Member] | May 2019 Warrant [Member]

Stockholders' Deficit (Details) [Line Items]

Conversion of notes into shares

31,740,704

78,740,157

125,739,610

Private Placement [Member]

Stockholders' Deficit (Details) [Line Items]

Number of private placements

2

Private placement amount received (in Dollars) | $

$ 6,600

First Quarter Two Thousands Eighteen Placement [Member] | Tranche One [Member]

Stockholders' Deficit (Details) [Line Items]

Private placement amount received (in Dollars) | $

$ 781

Stock issuance costs (in Dollars) | $

$ 63

First Quarter Two Thousands Eighteen Placement [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Private placement amount received (in Dollars) | $

$ 824

Stock issuance costs (in Dollars) | $

$ 40

First Quarter Two Thousands Eighteen Placement [Member] | Common Stock [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

1,175,612

First Quarter Two Thousands Eighteen Placement [Member] | Common Stock [Member] | Tranche One [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

569,341

First Quarter Two Thousands Eighteen Placement [Member] | Common Stock [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

606,271

First Quarter Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

58,780,619

Common stock issued, price per share (in Dollars per share) | $ / shares

$ 0.035

First Quarter Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Tranche One [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

28,467,063

First Quarter Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

30,313,556

First Quarter Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Crystal Amber Fund Limited [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

27,391,756

First Quarter Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Board Member [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

2,921,800

Autumn Two Thousands Eighteen Placement [Member] | Tranche One [Member]

Stockholders' Deficit (Details) [Line Items]

Private placement amount received (in Dollars) | $

$ 2,200

Stock issuance costs (in Dollars) | $

$ 56

Autumn Two Thousands Eighteen Placement [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Private placement amount received (in Dollars) | $

$ 2,800

Stock issuance costs (in Dollars) | $

$ 12

Autumn Two Thousands Eighteen Placement [Member] | Common Stock [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

6,944,445

Autumn Two Thousands Eighteen Placement [Member] | Common Stock [Member] | Tranche One [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

3,000,000

Autumn Two Thousands Eighteen Placement [Member] | Common Stock [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

3,944,445

Autumn Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

347,222,250

Common stock issued, price per share (in Dollars per share) | $ / shares

$ 0.020

Autumn Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Tranche One [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

150,000,000

Autumn Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

197,222,250

Autumn Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | UNITED STATES

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

23,819,450

Autumn Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | AUSTRALIA

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

5,208,350

Autumn Two Thousands Eighteen Placement [Member] | Chess Depositary Interests [Member] | Crystal Amber Fund Limited [Member] | Tranche Two [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued, shares

168,194,450

Share-Based Compensation (Detai

Share-Based Compensation (Details)	Oct. 29, 2019$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Aug. 31, 2011shares	Aug. 01, 2011shares
Share-Based Compensation (Details) [Line Items]
Number of stock-based compensation plans		2
Annual increase in number of shares available for grant		500,000
Percentage of common shares outstanding		4.00%
Number of shares available for issue, additional shares		500,000
Stock options, expire period		10 years
Amount of expected dividend yield (in Dollars) | $		$ 0
Percentage of stock option grants vest		25.00%
Weighted average grant date fair value (in Dollars per share) | $ / shares		$ 1.04	$ 0.97
Unrecognized compensation expense (in Dollars) | $		$ 2,400
Share based Compensation Arrangement by Share based Payment Award Options Weighted Average Expected Term		3 years 94 days
Share cancelled due to resignation of employee
Performance stock units outstanding		250,000	250,000
Stock-based compensation expense (in Dollars) | $		$ 388,000	$ 124,000
Options granted		1,994,771
Exercise price (in Dollars per share) | $ / shares		$ 1.08
Performance Shares [Member]
Share-Based Compensation (Details) [Line Items]
Number of shares of common stock to be received, per performance stock unit		1
Share cancelled due to resignation of employee		142,659
Performance stock units outstanding		250,000
Performance Stock Units [Member]
Share-Based Compensation (Details) [Line Items]
Unrecognized stock based compensation (in Dollars) | $		$ 200,000
Non Employees Awards [Member]
Share-Based Compensation (Details) [Line Items]
Unrecognized compensation expense (in Dollars) | $		0	180,000
Stock-based compensation expense (in Dollars) | $		$ 26,000	$ 20,000
NED Options [Member]
Share-Based Compensation (Details) [Line Items]
Options granted	30,000
Exercise price (in Dollars per share) | $ / shares	$ 1.34
2003 Stock Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award		922,086
2011 Stock Incentive Plan [Member]
Share-Based Compensation (Details) [Line Items]
Share reserved for incentive plan				450,000
Shares available for future grants		1,173,917			80,235

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Stock-Based Compensation - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 388	$ 124
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	77	6
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense		23
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 311	$ 95

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Weighted-average Assumptions used to Estimate Fair Value of Stock Options	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Weighted-average Assumptions used to Estimate Fair Value of Stock Options [Abstract]
Expected volatility	271.00%	120.70%
Expected term (in years)	6 years 18 days	6 years 18 days
Risk-free interest rate	1.80%	2.60%
Expected dividend yield	0.00%	0.00%

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Share-Based Activity	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Share-Based Activity [Abstract]
Outstanding, beginning balance (in Shares) | shares	1,142,883
Outstanding, beginning balance	$ 2.24
Outstanding, beginning balance	$ 2.20
Weighted average contractual life	8 years 175 days
Outstanding, beginning balance (in Dollars) | $
Outstanding, ending balance (in Shares) | shares	3,096,154
Outstanding, ending balance	$ 1.47
Outstanding, ending balance	$ 1.50
Weighted average contractual life	8 years 109 days
Outstanding, ending balance (in Dollars) | $
Vested or expected to vest at December 31, 2019 (in Shares) | shares	3,096,154
Vested or expected to vest at December 31, 2019 (in Dollars) | $
Exercisable at December 31, 2019 (in Shares) | shares	685,015
Exercisable at December 31, 2019	$ 2.86
Exercisable at December 31, 2019	$ 0.04
Weighted average contractual life, Exercisable	7 years 36 days
Exercisable (in Dollars) | $
Granted (in Shares) | shares	1,994,771
Granted	$ 1.08
Granted	$ 0.23
Exercised (in Shares) | shares
Exercised
Exercised
Cancelled (in Shares) | shares	(41,500)
Cancelled	$ 0.91
Cancelled	$ 0.91

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Restricted Stock Units and Performance Stock Units Activity $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)shares
Restricted Stock Units and Performance Stock Units Activity [Abstract]
Outstanding, beginning balance	250,000
Weighted average contractual life, at beginning of period	7 years 83 days
Outstanding Aggregate Intrinsic Value (in Dollars) | $	$ 141
Outstanding, ending balance	250,000
Weighted average contractual life, at end of period	6 years 83 days
Outstanding Aggregate Intrinsic Value (in Dollars) | $	$ 149
Granted
Exercised
Cancelled

Retirement Plans (Details)

Retirement Plans (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Retirement Plans (Details) [Line Items]
Defined contribution plan company contribution percentage	100.00%
Defined contribution plan cost recognized	$ 48	$ 24
International employees [Member]
Retirement Plans (Details) [Line Items]
Defined contribution plan company contribution percentage	100.00%
Defined contribution plan cost recognized	$ 9	$ 12

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes (Details) [Line Items]
U.S. federal statutory rate	21.00%
Unrecognized Tax Benefits	$ 1,480	$ 1,462	$ 1,481
UNITED STATES
Income Taxes (Details) [Line Items]
Deferred tax assets valuation allowance	73,700	70,800
Increase in deferred tax valuation allowance	2,900
Domestic Tax Authority [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforwards	248,800	$ 25,800	$ 25,800
Domestic Tax Authority [Member] | In Process Research and Development [Member]
Income Taxes (Details) [Line Items]
Tax credit carryforwards	3,800
State and Local Jurisdiction [Member]
Income Taxes (Details) [Line Items]
Net operating loss carryforwards	231,100
State and Local Jurisdiction [Member] | In Process Research and Development [Member]
Income Taxes (Details) [Line Items]
Tax credit carryforwards	$ 2,000
Earliest Tax Year [Member] | Domestic Tax Authority [Member]
Income Taxes (Details) [Line Items]
Operating loss carryforward expiration year	2024
Earliest Tax Year [Member] | State and Local Jurisdiction [Member]
Income Taxes (Details) [Line Items]
Operating loss carryforward expiration year	2030
Latest Tax Year [Member] | Domestic Tax Authority [Member]
Income Taxes (Details) [Line Items]
Operating loss carryforward expiration year	2038
Latest Tax Year [Member] | State and Local Jurisdiction [Member]
Income Taxes (Details) [Line Items]
Operating loss carryforward expiration year	2039

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of loss before provision for income taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule of loss before provision for income taxes [Abstract]
Domestic	$ (17,376)	$ (8,054)
Foreign	88	29
Total	$ (17,288)	$ (8,025)

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of provision for income taxes in accompanying consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Current Provision:
Federal
State	1	1
Foreign	42	13
Total	43	14
Deferred (Benefit) Provision:
Federal
State
Foreign	2	(1)
Total	2	(1)
Total provision	$ 45	$ 13

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of reconciliation of income taxes from operations computed using U.S. federal statutory rate - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule of reconciliation of income taxes from operations computed using U.S. federal statutory rate [Abstract]
Income tax benefit using U.S. federal statutory rate	$ (3,624)	$ (1,675)
State rate, net of federal benefit	(631)	(438)
Permanent differences
Nondeductible interest	1,052	36
Warrants	353
GILTI	8
Meals and entertainment	6	3
Other	2	1
Tax credits generated	(147)	(45)
Change in valuation allowance	2,888	2,041
Foreign rate differential	4	3
Other items	96	63
Stock compensation	38	24
Total provision	$ 45	$ 13

Income Taxes (Details) - Sche_4

Income Taxes (Details) - Schedule of net deferred tax assets and liabilities - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 66,859	$ 63,881
Research and development credit carryforwards	4,083	4,026
Capitalized research and development costs		123
Capitalized start-up expenses	2,133	2,490
Depreciation and other	635	305
Total deferred tax assets	73,710	70,825
Valuation allowance	(73,703)	(70,815)
Net deferred tax asset	$ 7	$ 10

Income Taxes (Details) - Sche_5

Income Taxes (Details) - Schedule of unrecognized tax benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule of unrecognized tax benefits [Abstract]
Unrecognized tax benefit – as of the beginning of the year	$ 1,462	$ 1,481
Gross decreases – expiration of underlying tax asset	(21)	(35)
Gross increases – current period tax positions	39	16
Unrecognized tax benefits – as of the end of the year	$ 1,480	$ 1,462

Subsequent Events (Details)

Subsequent Events (Details) $ in Millions	Jan. 13, 2020USD ($)
Subsequent Event [Member] | August 2019 Note [Member]
Subsequent Events (Details) [Line Items]
Notes receivable	$ 4.6